PubMedHealth treatment related to Leiomyoma, Uterine: 63
Fibroids usually only need to be treated if they are causing fertility problems or could cause problems during pregnancy. The choice of treatment will mainly depend on whether a woman would still like to have children – and how she sees the advantages and disadvantages of the various treatments. The severity of the symptoms and the size and position of the fibroids may also determine which treatments are an option.There is no rush to make a treatment decision. Fibroids usually grow very slowly. So you can take your time to read up on all of the pros and cons of the different treatments. Sometimes it is also a good idea to get several opinions from different doctors.The treatment goals may include the following:Reduce menstrual bleedingRelieve pain, cramps and tensionHelp with difficulties emptying the bladder and digestionPreserve or improve fertilityThe treatment options include:Hormone therapies: The main hormone therapies are hormonal contraceptives to reduce heavy menstrual bleeding, and hormones that prevent the production of estrogens (GnRH analogues).Surgical removal of the fibroid or the entire womb.Closing off the blood vessels that supply the fibroid with blood (uterine fibroid embolization). The aim is to shrink the fibroids.Other procedures like focused ultrasound surgery (FUS). This is a relatively new procedure, and its advantages and disadvantages have not yet been fully studied. FUS uses high-intensity ultrasound waves to heat and destroy the fibroid.Other treatments like painkillers, herbal remedies or acupuncture.NSAID (non-steroidal anti-inflammatory drug) painkillers like ibuprofen or diclofenac have been proven to relieve period pain. But there are no studies that have specifically looked into the effects of NSAIDs in women with fibroids. This is also true for acupuncture. Some herbal remedies have been studied more than others, but there's currently no evidence that they are effective in treating fibroids.
FDA approved drugs:
(show top 50)
(show all 240)
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Abraxane
18
49
|
PACLITAXEL |
Celgene |
October 2012 |
Disease/s that Drug Treats:non-small cell lung cancer
Indications and Usage:
18
ABRAXANE is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapyfor metastatic disease or relapse within 6 months of adjuvantchemotherapy. Prior therapy should have included an anthracyclineunless clinically contraindicated. (1.1) Locally advanced or metastatic non-small cell lung cancer (NSCLC),as first-line treatment in combination with carboplatin, in patients whoare not candidates for curative surgery or radiation therapy. (1.2) Metastatic adenocarcinoma of the pancreas as first-line treatment, incombination with gemcitabine. (1.3), ABRAXANE is a microtubule inhibitor indicated for the treatment of: * Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (1.1) * Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. (1.2) * Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. (1.3)
DrugBank Targets:
16
1. Apoptosis regulator Bcl-2;;2. Tubulin beta-1 chain;;3. Nuclear receptor subfamily 1 group I member 2;;4. Microtubule-associated protein 4;;5. Microtubule-associated protein 2; ;6. Microtubule-associated protein tau, Apoptosis regulator Bcl-2|Tubulin beta-1 chain|Nuclear receptor subfamily 1 group I member 2|Microtubule-associated protein 4|Microtubule-associated protein 2|Microtubule-associated protein tau|
Mechanism of Action:
18
Target: microtubule , microtubule
Action: inhibitor
FDA: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubulesby preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubulenetwork that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or âbundlesâ ofmicrotubules throughout the cell cycle and multiple asters of microtubules during mitosis. , ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or âbundlesâ of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
|
| 2 |
|
Abstral
18
|
FENTANYL (citrate) |
ProStrakan |
January 2011 |
Disease/s that Drug Treats:breakthrough cancer pain in opiod-tolerant patients
Indications and Usage:
18
ABSTRAL is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. (1) Limitations of Use: ABSTRAL may be dispensed only to patients enrolled in the TIRF REMS Access program.
DrugBank Targets:
16
1. Mu-type opioid receptor ;2. Delta-type opioid receptor;3. Kappa-type opioid receptor
Mechanism of Action:
18
Target: µ-opioid receptor (possible mechanism of action)
Action: agonist
FDA: Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the classknown as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, andhydrocodone.
|
| 3 |
|
Actiq
18
|
FENTANYL (citrate) |
Anesta Corporation |
November 1998 |
Disease/s that Drug Treats:cancer pain
Indications and Usage:
18
ACTIQ is an opioid agonist indicated for the management of breakthrough pain in cancer patients 16 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. (1) Limitations of Use: ACTIQ may be dispensed only to patients enrolled in the TIRF REMS Access program. (1)
DrugBank Targets:
16
1. Mu-type opioid receptor ;2. Delta-type opioid receptor;3. Kappa-type opioid receptor
Mechanism of Action:
18
Target: -
Action: agonist
FDA: Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.
|
| 4 |
|
Adcetris
18
49
|
BRENTUXIMAB VEDOTIN |
Seattle Genetics |
August 2011 |
Disease/s that Drug Treats:Hodgkin lymphoma and anaplastic large cell lymphoma
Indications and Usage:
18
ADCETRIS is a CD30-directed antibody-drug conjugate indicated fortreatment of patients with: Hodgkin lymphoma after failure of autologous stem cell transplant(ASCT) or after failure of at least two prior multi-agent chemotherapyregimens in patients who are not ASCT candidates (1.1). Systemic anaplastic large cell lymphoma after failure of at least oneprior multi-agent chemotherapy regimen (1.2).Accelerated approval was granted for the above indications based onoverall response rate. An improvement in patient-reported outcomes orsurvival has not been established. Continued approval for these indicationsmay be contingent upon verification and description of clinical benefit inconfirmatory trials.
DrugBank Targets:
16
Tumor necrosis factor receptor superfamily member 8
Mechanism of Action:
18
Target: microtubule
Action: disruptor
FDA: Brentuximab vedotin is an ADC. The antibody is a chimeric IgG1 directed against CD30. Thesmall molecule, MMAE, is a microtubule disrupting agent. MMAE is covalently attached to theantibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is dueto the binding of the ADC to CD30-expressing cells, followed by internalization of theADC-CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE totubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrestand apoptotic death of the cells.
|
| 5 |
|
Afinitor
18
49
|
EVEROLIMUS |
Novartis |
March 2009 |
Disease/s that Drug Treats:renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumors/ hormone receptor-positive, HER2-negative breast cancer
Indications and Usage:
18
AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:
16
Serine/threonine-protein kinase mTOR
Mechanism of Action:
18
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of thePI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellularprotein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition ofmTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiationfactor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate ofmTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independentactivation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) andreduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shownto reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitrostudies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activityof everolimus in a synergistic manner.Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
|
| 6 |
|
Akynzeo
18
49
|
NETUPITANT AND PALONOSETRON (hydrochloride) |
Helsinn |
October 2014 |
Disease/s that Drug Treats:chemotherapy-induced nausea and vomiting
Indications and Usage:
18
AKYNZEO is a fixed combination of netupitant, a substance P/neurokinin 1(NK1) receptor antagonist, and palonosetron, a serotonin-3 (5-HT3) receptorantagonist indicated for the prevention of acute and delayed nausea andvomiting associated with initial and repeat courses of cancer chemotherapy,including, but not limited to, highly emetogenic chemotherapy. Oralpalonosetron prevents nausea and vomiting during the acute phase andnetupitant prevents nausea and vomiting during both the acute and delayedphase after cancer chemotherapy. (1)
DrugBank Targets:
16
1. Substance-P receptor;2. 5-hydroxytryptamine receptor 3A
Mechanism of Action:
18
Target: neurokinin 1 (NK1) receptors/ substance P mediated responses [netupitant] & 5-HT3 receptor [palonosetron]
Action: activator/ inhibitor & agonist
FDA: Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK1) receptors.Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or noaffinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea andvomiting, particularly when certain agents, such as cisplatin, are used. 5-HT3 receptors are located on thenerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the areapostrema. Chemotherapeutic agents produce nausea and vomiting by stimulating the release of serotoninfrom the enterochromaffin cells of the small intestine. Serotonin then activates 5-HT3 receptors located onvagal afferents to initiate the vomiting reflex. The development of acute emesis is known to depend onserotonin and its 5-HT3 receptors have been demonstrated to selectively stimulate the emetic response.Delayed emesis has been largely associated with the activation of tachykinin family neurokinin 1 (NK1)receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown inin vitro and in vivo studies, netupitant inhibits substance P mediated responses.
|
| 7 |
|
Alimta
18
49
|
PEMETREXED (also Pemetrexed Disodium) |
Eli Lilly |
February 2004 |
Disease/s that Drug Treats:Mesothelioma
Indications and Usage:
18
ALIMTA® is a folate analog metabolic inhibitor indicated for: Locally Advanced or Metastatic Nonsquamous Non-Small CellLung Cancer: Initial treatment in combination with cisplatin. (1.1) Maintenance treatment of patients whose disease has notprogressed after four cycles of platinum-based first-linechemotherapy. (1.2) After prior chemotherapy as a single-agent. (1.3) Mesothelioma: in combination with cisplatin. (1.4)Limitations of Use: ALIMTA is not indicated for the treatment of patients withsquamous cell non-small cell lung cancer. (1.5)
DrugBank Targets:
16
1. Thymidylate synthase;2. Bifunctional purine biosynthesis protein PURH;3. Dihydrofolate reductase;4. Trifunctional purine biosynthetic protein adenosine-3
Mechanism of Action:
18
Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase
Action: antagonist/ inhibitor
FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependentmetabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibitsthymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate bindingprotein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzymefolylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to alesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-liferesulting in prolonged drug action in malignant cells.
|
| 8 |
|
Aloxi
18
49
|
PALONOSETRON (hydrochloride) |
MGI Pharma, Helsinn Healthcare |
August 2003 |
Disease/s that Drug Treats:Chemotherapy side effects
Indications and Usage:
18
ALOXI is a serotonin-3 (5-HT3) receptor antagonist indicated in adults for: Moderately emetogenic cancer chemotherapy -- prevention ofacute and delayed nausea and vomiting associated with initial andrepeat courses (1.1) Highly emetogenic cancer chemotherapy -- prevention of acutenausea and vomiting associated with initial and repeat courses(1.1) Prevention of postoperative nausea and vomiting (PONV) for upto 24 hours following surgery. Efficacy beyond 24 hours has notbeen demonstrated (1.3)ALOXI is indicated in pediatric patients aged 1 month to less than 17 yearsfor: Prevention of acute nausea and vomiting associated with initialand repeat courses of emetogenic cancer chemotherapy, includinghighly emetogenic cancer chemotherapy (1.2)
DrugBank Targets:
16
5-hydroxytryptamine receptor 3A
Mechanism of Action:
18
Target: serotonin subtype 3 (5-HT3) receptor/ ion channels involved in ventricular polarization
Action: antagonist/ blocker
FDA: Palonosetron is a 5-HT3 receptor antagonist with a strong bindingaffinity for this receptor and little or no affinity for other receptors.Cancer chemotherapy may be associated with a high incidence ofnausea and vomiting, particularly when certain agents, such as cisplatin, areused. 5-HT3 receptors are located on the nerve terminals of the vagus in theperiphery and centrally in the chemoreceptor trigger zone of the areapostrema. It is thought that chemotherapeutic agents produce nausea andvomiting by releasing serotonin from the enterochromaffin cells of the smallintestine and that the released serotonin then activates 5-HT3 receptorslocated on vagal afferents to initiate the vomiting reflex.Postoperative nausea and vomiting is influenced by multiple patient,surgical and anesthesia related factors and is triggered by release of 5-HT ina cascade of neuronal events involving both the central nervous system andthe gastrointestinal tract. The 5-HT3 receptor has been demonstrated toselectively participate in the emetic response.
|
| 9 |
|
Anzemet
18
|
DOLASETRON MESYLATE |
Hoechst Marion Roussel |
February 1998 |
Disease/s that Drug Treats:prevention of nausea and vomiting associated with chemotherapy and surgery/ Treatment for chemotherapy induced emesis
Indications and Usage:
18
ANZEMET Tablets are indicated for the prevention of nausea and vomiting associated withmoderately emetogenic cancer chemotherapy, including initial and repeat courses in adults andchildren 2 years and older.
DrugBank Targets:
16
5-hydroxytryptamine receptor 3A
Mechanism of Action:
18
Target: seratonin 5-HT3 receptor
Action: antagonist
FDA: Dolasetron mesylate and its active metabolite, hydrodolasetron (MDL 74,156), are selectiveserotonin 5-HT3 receptor antagonists not shown to have activity at other known serotoninreceptors and with low affinity for dopamine receptors. The serotonin 5-HT3 receptors arelocated on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptortrigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea andvomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and thatthe released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate thevomiting reflex.In healthy volunteers (N=64), dolasetron mesylate in single intravenous doses up to 5 mg/kgproduced no effect on pupil size or meaningful changes in EEG tracings. Results fromneuropsychiatric tests revealed that dolasetron mesylate did not alter mood or concentration.Multiple daily doses of dolasetron have had no effect on colonic transit in humans. Dolasetronhas no effect on plasma prolactin concentrations.
|
| 10 |
|
Aredia
18
49
|
PAMIDRONATE DISODIUM |
Chiron |
August 1996 |
Disease/s that Drug Treats:osteolytic bone metastases of breast cancer
Indications and Usage:
18
Hypercalcemia of MalignancyAredia, in conjunction with adequate hydration, is indicated for the treatment of moderate or severehypercalcemia associated with malignancy, with or without bone metastases. Patients who have eitherepidermoid or non-epidermoid tumors respond to treatment with Aredia. Vigorous saline hydration, anintegral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made torestore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia maybe treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patientsshould be hydrated adequately throughout the treatment, but overhydration, especially in those patientswho have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction ofhypovolemia. The safety and efficacy of Aredia in the treatment of hypercalcemia associated withhyperparathyroidism or with other non-tumor-related conditions has not been established.Pagetâs DiseaseAredia is indicated for the treatment of patients with moderate to severe Pagetâs disease of bone. Theeffectiveness of Aredia was demonstrated primarily in patients with serum alkaline phosphatase â¥3 timesthe upper limit of normal. Aredia therapy in patients with Pagetâs disease has been effective in reducingserum alkaline phosphatase and urinary hydroxyproline levels by â¥50% in at least 50% of patients, and byâ¥30% in at least 80% of patients. Aredia therapy has also been effective in reducing these biochemicalmarkers in patients with Pagetâs disease who failed to respond, or no longer responded to othertreatments.Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of MultipleMyelomaAredia is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolyticbone metastases of breast cancer and osteolytic lesions of multiple myeloma. The Aredia treatment effectappeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the studyof those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated(see CLINICAL PHARMACOLOGY, Osteolytic Bone Metastases of Breast Cancer and OsteolyticLesions of Multiple Myeloma, Clinical Trials section).
DrugBank Targets:
16
1. Farnesyl pyrophosphate synthase;2. Hydroxylapatite
Mechanism of Action:
18
Target: bone resorption; FPP synthase
Action: inhibitor
FDA: The principal pharmacologic action of Aredia is inhibition of bone resorption. Although the mechanism ofantiresorptive action is not completely understood, several factors are thought to contribute to this action.Aredia adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolutionof this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activitycontributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment ofhypercalcemia, Aredia inhibits bone resorption apparently without inhibiting bone formation andmineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that Arediainhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by varioustumors in animal studies.
|
| 11 |
|
Arimidex
18
49
|
ANASTROZOLE |
AstraZeneca |
January 1996 |
Disease/s that Drug Treats:post menopausal breast cancer
Indications and Usage:
18
ARIMIDEX is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women withhormone receptor-positive early breast cancer (1.1) First-line treatment of postmenopausal women withhormone receptor-positive or hormone receptor unknownlocally advanced or metastatic breast cancer (1.2) Treatment of advanced breast cancer in postmenopausalwomen with disease progression following tamoxifentherapy. Patients with ER-negative disease and patientswho did not respond to previous tamoxifen therapy rarelyresponded to ARIMIDEX (1.3)
DrugBank Targets:
16
Cytochrome P450 19A1
Mechanism of Action:
18
Target: oral aromatase
Action: inhibitor
FDA: The growth of many cancers of the breast is stimulated or maintained by estrogens.In postmenopausal women, estrogens are mainly derived from the action of the aromataseenzyme, which converts adrenal androgens (primarily androstenedione and testosterone) toestrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and inthe cancer tissue itself can therefore be achieved by specifically inhibiting the aromataseenzyme.Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serumestradiol concentrations and has no detectable effect on formation of adrenal corticosteroidsor aldosterone.
|
| 12 |
|
Aromasin Tablets
18
49
|
EXEMESTANE |
Pharmacia & Upjohn |
October 21. 1999 |
Disease/s that Drug Treats:advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Indications and Usage:
18
AROMASIN is an aromatase inhibitor indicated for: Incidences of cardiac ischemic events (myocardial infarction, angina, adjuvant treatment of postmenopausal women with estrogen-receptor and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%.positive early breast cancer who have received two to three years of Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6,tamoxifen and are switched to AROMASIN for completion of a total of 6.1).five consecutive years of adjuvant hormonal therapy (14.1). Advanced breast cancer: Most common adverse events were mild to treatment of advanced breast cancer in postmenopausal women whose moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%),disease has progressed following tamoxifen therapy (14.2).
DrugBank Targets:
16
Cytochrome P450 19A1
Mechanism of Action:
18
Target: steroidal aromatase
Action: inactivator
FDA: Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that convertsandrogens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarilyestradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausalwomen is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens(estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromataseinhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breastcancer.Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrateandrostenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that bindsirreversibly to the active site of the enzyme, causing its inactivation, an effect also known as âsuicide inhibition.âExemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has nodetectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on otherenzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibitingthe aromatase enzyme.
|
| 13 |
|
Arranon
18
49
|
NELARABINE |
GlaxoSmithKline |
October 2005 |
Disease/s that Drug Treats:Lymphoblastic Leukemia
Indications and Usage:
18
ARRANON is a nucleoside metabolic inhibitor indicated for the treatment ofpatients with T-cell acute lymphoblastic leukemia and T-cell lymphoblasticlymphoma whose disease has not responded to or has relapsed followingtreatment with at least two chemotherapy regimens. This use is based on theinduction of complete responses. Randomized trials demonstrating increasedsurvival or other clinical benefit have not been conducted. (1)
Mechanism of Action:
18
Target: DNA synthesis
Action: disruptor --> apoptosis
FDA: Nelarabine is a pro-drug of the deoxyguanosine analogue 9-β-D-arabinofuranosylguanine266 (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by adenosine deaminase267 (ADA) to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and268 subsequently converted to the active 5â-triphosphate, ara-GTP. Accumulation of ara-GTP in269 leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition270 of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and271 systemic toxicity of nelarabine.
|
| 14 |
|
Arzerra
18
49
|
OFATUMUMAB |
GlaxoSmithKline |
October 2009 |
Disease/s that Drug Treats:chronic lymphocytic leukemia
Indications and Usage:
18
ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibodyindicated: in combination with chlorambucil, for the treatment of previouslyuntreated patients with chronic lymphocytic leukemia (CLL) for whomfludarabine-based therapy is considered inappropriate. (1.1) for the treatment of patients with CLL refractory to fludarabine andalemtuzumab. (1.2)
DrugBank Targets:
16
no entry
Mechanism of Action:
18
Target: B-cell
Action: promotes lysis
FDA: Ofatumumab binds specifically to both the small and large extracellular loops of the CD20402 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature403 B-lymphocyte) and on B-cell CLL. The CD20 molecule is not shed from the cell surface and is404 not internalized following antibody binding.405406 The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates407 immune effector functions to result in B-cell lysis in vitro. Data suggest that possible408 mechanisms of cell lysis include complement-dependent cytotoxicity and antibody-dependent,409 cell-mediated cytotoxicity.
|
| 15 |
|
Avastin
18
49
|
BEVACIZUMAB |
Genentech |
July 2009 |
Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer
Indications and Usage:
18
Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1)
DrugBank Targets:
16
1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
18
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
|
| 16 |
|
Beleodaq
18
49
|
BELINOSTAT |
Spectrum Pharmaceuticals |
July 2014 |
Disease/s that Drug Treats:relapsed or refractory peripheral T-cell lymphoma
Indications and Usage:
18
Beleodaq is a histone deacetylase inhibitor indicated for the treatment ofpatients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Thisindication is approved under accelerated approval based on tumor responserate and duration of response. An improvement in survival or disease-relatedsymptoms has not been established. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit in theconfirmatory trial. (1)
DrugBank Targets:
16
no entry
Mechanism of Action:
18
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from thelysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation ofacetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells.Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibitedthe enzymatic activity of histone deacetylases at nanomolar concentrations (<250 nM).
|
| 17 |
|
Bexxar
18
49
|
TOSITUMOMAB; IODINE I 131 TOSITUMOMAB |
Corixa |
June 2003 |
Disease/s that Drug Treats:Non-Hodgkin's Lymphoma
Indications and Usage:
18
BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directedradiotherapeutic antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed nonHodgkin'slymphoma who have progressed during or after rituximab therapy,including patients with rituximab-refractory non-Hodgkin's lymphoma. (1.1)Determination of the effectiveness of the BEXXAR therapeutic regimen isbased on overall response rates in patients whose disease is refractory tochemotherapy and rituximab. The effects of the BEXXAR therapeuticregimen on survival are not known. (1.1)Important Limitation of Use BEXXAR therapeutic regimen is only indicated for a single course oftreatment and is not indicated for a first-line treatment. (1.2)
DrugBank Targets:
16
1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10.Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
18
Target: CD20
Action: cytotoxic antibody
FDA: Tositumomab binds specifically to an epitope within the extracellular domain of the586 CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B lymphocytes587 to mature B lymphocytes) and on B-cell non-Hodgkin's lymphomas. The CD20 molecule is not588 shed from the cell surface and is not internalized following antibody binding. The BEXXAR589 therapeutic regimen induces cell death by emitting ionizing radiation to CD20-expressing590 lymphocytes or neighboring cells. In addition to cell death mediated by the radioisotope, other591 possible mechanisms of action include antibody-dependent cellular cytotoxicity, complement-592 dependent cytotoxicity, and CD20-mediated apoptosis.
|
| 18 |
|
Blincyto
18
49
|
BLINATUMOMAB |
Amgen |
December 2014 |
Disease/s that Drug Treats:Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia
Indications and Usage:
18
BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated forthe treatment of Philadelphia chromosome-negative relapsed or refractory Bcellprecursor acute lymphoblastic leukemia (ALL). This indication isapproved under accelerated approval. Continued approval for this indicationmay be contingent upon verification of clinical benefit in subsequent trials. (1)
DrugBank Targets:
16
1. B-lymphocyte antigen CD19;2. T-cell surface glycoprotein CD3 delta chain
Mechanism of Action:
18
Target: CD19-directed CD3 T-cell
Action: engager
FDA: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on thesurface of cells of B-lineage origin and CD3 expressed on the surface of T cells. It activates endogenousT cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant Bcells. Blinatumomab mediates the formation of a synapse between the T cell and the tumor cell,upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatorycytokines, and proliferation of T cells, which result in redirected lysis of CD19+ cells.
|
| 19 |
|
Bosulif
18
49
|
BOSUTINIB MONOHYDRATE |
Pfizer |
September 2012 |
Disease/s that Drug Treats:Ph+ chronic myelogenous leukemia
Indications and Usage:
18
BOSULIF is a kinase inhibitor indicated for the treatment of adult patientswith chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia(CML) with resistance or intolerance to prior therapy. (1)
DrugBank Targets:
16
1. Breakpoint cluster region protein;2. Tyrosine-protein kinase ABL1;3. Tyrosine-protein kinase Lyn;4. Tyrosine-protein kinase HCK;5. Proto-oncogene tyrosine-protein kinase Src;6. Cyclin-dependent kinase 2;7. Dual specificity mitogen-activated protein kinase kinase 1;8. Dual specificity mitogen-activated protein kinase kinase 2;9. Mitogen-activated protein kinase kinase kinase 2;10. Calcium/calmodulin-dependent protein kinase type II subunit gamma
Mechanism of Action:
18
Target: tyrosine kinase/ Src-family kinases including Src, Lyn, and Hck
Action: inhibitor
FDA: Bosutinib is a tyrosine kinase inhibitor. Bosutinib inhibits the Bcr-Abl kinase that promotes CML; it is also aninhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms ofBcr-Abl expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L mutant cells. In mice,treatment with bosutinib reduced the size of CML tumors relative to controls and inhibited growth of murine myeloidtumors expressing several imatinib-resistant forms of Bcr-Abl.
|
| 20 |
|
Bromfenac
18
|
BROMFENAC SODIUM |
Duract, Wyeth-Ayerst Laboratories |
July 1997 |
Disease/s that Drug Treats:acute pain
Indications and Usage:
18
Bromfenac Ophthalmic Solutionis a nonsteroidal anti-inflamatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction (1).
DrugBank Targets:
16
1. Prostaglandin G/H synthase 2;2. Prostaglandin G/H synthase 1
Mechanism of Action:
18
Target: cyclooxygenas 1 and 2
Action: inhibitor
FDA: Bromfenac is a non-steroidal anti-inflamatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis bby inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produces disruption of the blood aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
|
| 21 |
|
Busulfex
18
49
|
BUSULFAN |
Orphan Medical |
February 1999 |
Disease/s that Drug Treats:leukemia
Indications and Usage:
18
BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimenprior to allogeneic hematopoietic progenitor cell transplantation forchronic myelogenous leukemia (CML) (1)
Mechanism of Action:
18
Target: DNA
Action: alkylyzer
FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of afour-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This producesreactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity ofbusulfan.
|
| 22 |
|
Campath
18
49
|
ALEMTUZUMAB |
Berlex Laboratories |
May 2001 |
Disease/s that Drug Treats:Leukemia
Indications and Usage:
18
LEMTRADA is a CD52-directed cytolytic monoclonal antibody indicated dizziness, abdominal pain, flushing, and vomiting. (6.1) for the treatment of patients with relapsing forms of multiple sclerosis(MS).
DrugBank Targets:
16
1. CAMPATH-1 antigen;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;;
Mechanism of Action:
18
Target: CD52 antigen
Action: after binding, induces cell lysis
FDA: The precise mechanism by which alemtuzumab exerts its therapeutic effects in multiple490 sclerosis is unknown but is presumed to involve binding to CD52, a cell surface antigen491 present on T and B lymphocytes, and on natural killer cells, monocytes, and492 macrophages. Following cell surface binding to T and B lymphocytes, alemtuzumab493 results in antibody-dependent cellular cytolysis and complement-mediated lysis.
|
| 23 |
|
Campostar
18
49
|
IRINOTECAN HYDROCHLORIDE |
Pharmacia & Upjohn |
June 1996 |
Disease/s that Drug Treats:metastatic colorectal cancer
Indications and Usage:
18
CAMPTOSAR is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin forpatients with metastatic carcinoma of the colon or rectum. (1) Patients with metastatic carcinoma of the colon or rectum whose diseasehas recurred or progressed following initial fluorouracil-based therapy. (1)
DrugBank Targets:
16
1. DNA topoisomerase I, mitochondrial;2. DNA topoisomerase 1
Mechanism of Action:
18
Target: topoisomerase I-DNA complex
Action: inhibitor of repairs to DNA
FDA: Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzymetopoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strandbreaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complexand prevent religation of these single-strand breaks. Current research suggests that thecytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesiswhen replication enzymes interact with the ternary complex formed by topoisomerase I, DNA,and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strandbreaks.
|
| 24 |
|
CEA-Scan
18
|
|
Immunomedics |
April 1996 |
Disease/s that Drug Treats:colorectal cancer
Indications and Usage:
18
DrugBank Targets:
16
1. Carcinoembryonic antigen-related cell adhesion molecule 1
Mechanism of Action:
18
Target: carcinoembryonic antigen (""CEA"")
Action: marks
FDA: -
|
| 25 |
|
Cervarix
18
49
|
Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant |
GlaxoSmithKline |
October 2009 |
Disease/s that Drug Treats:prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:
18
DrugBank Targets:
-
Mechanism of Action:
18
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
|
| 26 |
|
Clolar
18
49
|
CLOFARABINE |
Genzyme |
December, 2004 |
Disease/s that Drug Treats:Lymphoblastic Leukemia
Indications and Usage:
18
Clolar (clofarabine) injection is a purine nucleoside metabolic inhibitorindicated for the treatment of pediatric patients 1 to 21 years old with relapsedor refractory acute lymphoblastic leukemia after at least two prior regimens.This indication is based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with Clolar.(1)
DrugBank Targets:
16
1. DNA polymerase alpha catalytic subunit;2. Ribonucleoside-diphosphate reductase large subunit;3. DNA
Mechanism of Action:
18
Target: ribonucleotide reductase
Action: inhibitor
FDA: Clofarabine is sequentially metabolized intracellularly to the 5â-monophosphate metabolite bydeoxycytidine kinase and mono- and di-phospho-kinases to the active 5â-triphosphate metabolite.Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equalto or greater than that of the natural substrate, deoxycytidine. Clofarabine inhibits DNA synthesisby decreasing cellular deoxynucleotide triphosphate pools through an inhibitory action onribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair throughincorporation into the DNA chain by competitive inhibition of DNA polymerases. The affinity ofclofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosinetriphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNArepair by incorporation into the DNA chain during the repair process. Clofarabine 5â-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of thepro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading toprogrammed cell death.Clofarabine is cytotoxic to rapidly proliferating and quiescent cancer cell types in vitro.
|
| 27 |
|
Cometriq
18
49
|
CABOZANTINIB S-MALATE |
Exelixis |
November 2012 |
Disease/s that Drug Treats:thyroid cancer
Indications and Usage:
18
COMETRIQ is a kinase inhibitor indicated for the treatment ofpatients with progressive, metastatic medullary thyroid cancer(MTC). (1)
DrugBank Targets:
16
1. Hepatocyte growth factor receptor;2. Vascular endothelial growth factor receptor 2;3. Proto-oncogene tyrosine-protein kinase receptor Ret
Mechanism of Action:
18
Target: tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2
Action: inhibitor
FDA: In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosinekinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2.These receptor tyrosine kinases are involved in both normal cellular function and pathologicprocesses such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumormicroenvironment.
|
| 28 |
|
Cyramza
18
49
|
RAMUCIRUMAB |
Eli Lilly |
April 2014 |
Disease/s that Drug Treats:gastric cancer
Indications and Usage:
18
CYRAMZA® is a human vascular endothelial growth factor receptor 2antagonist indicated as a single agent or in combination with paclitaxel, for treatmentof advanced gastric or gastro-esophageal junctionadenocarcinoma, with disease progression on or after priorfluoropyrimidine- or platinum-containing chemotherapy. (1.1) in combination with docetaxel, for treatment of metastatic nonsmallcell lung cancer with disease progression on or afterplatinum-based chemotherapy. Patients with EGFR or ALKgenomic tumor aberrations should have disease progression onFDA-approved therapy for these aberrations prior to receivingCYRAMZA. (1.2) in combination with FOLFIRI, for the treatment of metastaticcolorectal cancer with disease progression on or after priortherapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.(1.3)
DrugBank Targets:
-
Mechanism of Action:
18
Target: ligand-stimulated activation of VEGF Receptor 2
Action: inhibitor
FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulatedactivation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of humanendothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
|
| 29 |
|
Degarelix
18
49
|
degarelix |
Ferring Pharmaceuticals |
December of 2008 |
Disease/s that Drug Treats:Prostate Cancer
Indications and Usage:
18
DrugBank Targets:
16
1. Gonadotropin-releasing hormone receptor
Mechanism of Action:
18
Target: Gonadotropin-releasing hormone (GnRH) receptor
Action: antagonist
FDA: -
|
| 30 |
|
Doxil
18
49
|
DOXORUBICIN HYDROCHLORIDE |
Alza |
June 1999 |
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:
18
DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposiâs Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:
16
1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:
18
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
|
| 31 |
|
Elitek
18
49
|
RASBURICASE |
sanofi-aventis |
October 2009 |
Disease/s that Drug Treats:management of plasma uric acid levels in adults with malignancies
Indications and Usage:
18
Elitek is a recombinant urate-oxidase indicated for initial management ofplasma uric acid levels in pediatric and adult patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancertherapy expected to result in tumor lysis and subsequent elevation of plasmauric acid (1).Limitation of use: Elitek is indicated only for a single course of treatment (1).
DrugBank Targets:
16
1. Uric acid
Mechanism of Action:
18
Target: uric acid
Action: converter to alantoin
FDA: In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzesenzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite(allantoin).
|
| 32 |
|
Ellence
18
49
|
EPIRUBICIN HYDROCHLORIDE |
Pharmacia & Upjohn |
September 1999 |
Disease/s that Drug Treats:Component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer
Indications and Usage:
18
ELLENCE Injection is an anthracycline topoisomerase II inhibitor indicatedas a component of adjuvant therapy in patients with evidence of axillary nodetumor involvement following resection of primary breast cancer (1).
DrugBank Targets:
16
1. Chromodomain-helicase-DNA-binding protein 1;2. DNA topoisomerase 2-alpha;3. DNA
Mechanism of Action:
18
Target: nucleic acid (DNA and RNA) and protein synthesis
Action: inhibitor
FDA: Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical andbiological functions within eukaryotic cells, the precise mechanisms of epirubicinâs cytotoxic and/or antiproliferative properties have not beencompletely elucidated.Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleicacid (DNA and RNA) and protein synthesis.Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity,preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved inoxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to resultfrom these or other possible mechanisms.Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also activein vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.
|
| 33 |
|
Eloxatin
18
49
|
OXALIPLATIN |
Sanofi-aventis |
August 2002 |
Disease/s that Drug Treats:Metastatic colon or rectum carcinomas that have recurred or progressed within six months folowing first-line treatment
Indications and Usage:
18
ELOXATIN is a platinum-based drug used in combination with infusional 5-fluorouracil /leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who haveundergone complete resection of the primary tumor. (1) treatment of advanced colorectal cancer. (1)
DrugBank Targets:
16
1. DNA
Mechanism of Action:
18
Target: DNA replication and transcription
Action: inhibitor
FDA: Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives viadisplacement of the labile oxalate ligand. Several transient reactive species are formed, includingmonoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both interandintrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions oftwo adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by anintervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription.Cytotoxicity is cell-cycle nonspecific.In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. Incombination with 5-fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activitygreater than either compound alone in several tumor models [HT29 (colon), GR (mammary), andL1210 (leukemia)].
|
| 34 |
|
Emend
18
49
|
APREPITANT FOSAPREPITANT DIMEGLUMINE |
Merck |
March 2003 |
Disease/s that Drug Treats:Chemotherapy-induced Nausea and Vomiting
Indications and Usage:
18
EMEND® is a substance P/neurokinin 1 (NK1) receptor antagonist,indicated: in combination with other antiemetic agents for the:o prevention of acute and delayed nausea and vomitingassociated with initial and repeat courses of highly emetogeniccancer chemotherapy (HEC) including high-dose cisplatin (1.1)o prevention of nausea and vomiting associated with initial andrepeat courses of moderately emetogenic cancer chemotherapy(MEC) (1.1) for the prevention of postoperative nausea and vomiting (PONV)(1.2)Limitations of Use (1.3) Not studied for the treatment of established nausea and vomiting. Chronic continuous administration is not recommended.
DrugBank Targets:
16
1. Substance-P receptor
Mechanism of Action:
18
Target: emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin
Action: inhibitor
FDA: Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targetsof existing therapies for chemotherapy-induced nausea and vomiting (CINV) and postoperative nauseaand vomiting (PONV).Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxicchemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron EmissionTomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupiesbrain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity ofthe 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both theacute and delayed phases of cisplatin-induced emesis.
|
| 35 |
|
Erbitux
18
49
|
CETUXIMAB |
Imclone, Bristol-Myers Squibb |
February 2004 |
Disease/s that Drug Treats:Colorectal Cancer
Indications and Usage:
18
Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicatedfor treatment of:Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the headand neck in combination with radiation therapy. (1.1, 14.1) Recurrent locoregional disease or metastatic squamous cell carcinomaof the head and neck in combination with platinum-based therapy with5-FU. (1.1, 14.1) Recurrent or metastatic squamous cell carcinoma of the head and neckprogressing after platinum-based therapy. (1.1, 14.1)Colorectal CancerK-Ras wild-type, EGFR-expressing, metastatic colorectal cancer asdetermined by FDA-approved tests in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory toirinotecan-based chemotherapy, as a single agent in patients who have failed oxaliplatin- andirinotecan-based chemotherapy or who are intolerant to irinotecan.(1.2, 5.7, 12.1, 14.2)Limitation of Use: Erbitux is not indicated for treatment of Ras-mutantcolorectal cancer. (5.7, 14.2)
DrugBank Targets:
16
1. Epidermal growth factor receptor;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
18
Target: binding of epidermal growth factor (EGF) and other ligands to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1)
Action: inhibitor
FDA: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembraneglycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR,HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelialtissues, including the skin and hair follicle. Expression of EGFR is also detected in many humancancers including those of the head and neck, colon, and rectum. Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitivelyinhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforminggrowth factor-alpha. In vitro assays and in vivo animal studies have shown that binding ofcetuximab to the EGFR blocks phosphorylation and activation of receptor-associated kinases,resulting in inhibition of cell growth, induction of apoptosis, and decreased matrixmetalloproteinase and vascular endothelial growth factor production. Signal transduction throughthe EGFR results in activation of wild-type Ras proteins, but in cells with activating Ras somaticmutations, the resulting mutant Ras proteins are continuously active regardless of EGFRregulation.In vitro, cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC) against certainhuman tumor types. In vitro assays and in vivo animal studies have shown that cetuximabinhibits the growth and survival of tumor cells that express the EGFR. No anti-tumor effects ofcetuximab were observed in human tumor xenografts lacking EGFR expression. The addition ofcetuximab to radiation therapy or irinotecan in human tumor xenograft models in mice resultedin an increase in anti-tumor effects compared to radiation therapy or chemotherapy alone.
|
| 36 |
|
Erivedge
18
49
|
VISMODEGIB |
Genentech |
January 2012 |
Disease/s that Drug Treats:basal cell carcinoma
Indications and Usage:
18
ERIVEDGE (vismodegib) capsule is a hedgehog pathway inhibitor indicatedfor the treatment of adults with metastatic basal cell carcinoma, or with locallyadvanced basal cell carcinoma that has recurred following surgery or who arenot candidates for surgery, and who are not candidates for radiation. (1)
DrugBank Targets:
16
1. Smoothened homolog
Mechanism of Action:
18
Target: hedgehog (Hh) signaling pathway
Action: innhibitor
FDA: Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibitsSmoothened, a transmembrane protein involved in Hedgehog signal transduction.
|
| 37 |
|
Erwinaze
18
49
|
asparaginase Erwinia chrysanthemi |
Eusa Pharma |
November of 2011 |
Disease/s that Drug Treats:acute lymphoblastic leukemia
Indications and Usage:
18
ERWINAZE (asparaginase Erwinia chrysanthemi) is an asparagine specificenzyme indicated as a component of a multi-agent chemotherapeutic regimenfor the treatment of patients with acute lymphoblastic leukemia (ALL) whohave developed hypersensitivity to E. coli-derived asparaginase. (1)
DrugBank Targets:
-
Mechanism of Action:
18
Target: deamidation of asparagine to aspartic acid and ammonia
Action: catalyzer
FDA: Asparaginase Erwinia chrysanthemi catalyzes the deamidation of asparagine to aspartic acid and ammonia, resultingin a reduction in circulating levels of asparagine. The mechanism of action of ERWINAZE is thought to be based onthe inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity, resulting incytotoxicity specific for leukemic cells that depend on an exogenous source of amino acid asparagine for theirprotein metabolism and survival.
|
| 38 |
|
Ethyol
18
|
AMIFOSTINE |
Alza |
December 8, 1995 |
Disease/s that Drug Treats:ovarian cancer
Indications and Usage:
18
ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated withrepeated administration of cisplatin in patients with advanced ovarian cancer.ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patientsundergoing post-operative radiation treatment for head and neck cancer, where the radiationport includes a substantial portion of the parotid glands (see Clinical Studies).For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin basedchemotherapy regimens or radiation therapy is altered by ETHYOL. There are at present only limiteddata on the effects of ETHYOL on the efficacy of chemotherapy or radiotherapy in other settings.ETHYOL should not be administered to patients in other settings where chemotherapy can produce asignificant survival benefit or cure, or in patients receiving definitive radiotherapy, except in thecontext of a clinical study (see WARNINGS).
DrugBank Targets:
16
1. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1;2. Alkaline phosphatase, placental-like
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 39 |
|
Eulexin
18
|
FLUTAMIDE |
Schering-Plough |
June 1996 |
Disease/s that Drug Treats:prostate cancer
Indications and Usage:
18
EULEXIN capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B2C and Stage D2 metastatic carcinoma of the prostate. Stage B2C Prostatic Carcinoma: Treatment with EUlEXIN an the goserelin acetate implant shouls start 8 weeks prior to initiating radiation therapy and continue during radiation therapy. Stage D2 Metastatic Carcinoma: To acheive benefit from treatment, EULEXIN Capsules should be initiated with the LHRH-agonist and continued until progression.
DrugBank Targets:
16
1. Androgen receptor;2. Aryl hydrocarbon receptor
Mechanism of Action:
18
Target: androgen uptake and/or nuclear binding of angrogen in target tissues
Action: inhibitor
FDA: In animal studies, flutamide demonstrates potent anti-angrogenic effects. It exerts an antiandrogenic action by inhibiting angrogen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, eg. castration. Elevations of plasma testosterone and estraidiol levels have been noted following flutamide administration.
|
| 40 |
|
Evista
18
49
|
RALOXIFENE HYDROCHLORIDE |
Eli Lilly |
September 2007 |
Disease/s that Drug Treats:osteoporosis and reduction of breast cancer risk in postmenopausal women
Indications and Usage:
18
EVISTA is an estrogen agonist/antagonist indicated for Treatment and prevention of osteoporosis in postmenopausal women.(1.1)
DrugBank Targets:
16
1. Estrogen receptor;2. Estrogen receptor beta
Mechanism of Action:
18
Target: estrogenic pathways
Action: can be an activator or antooagonist
FDA: Decreases in estrogen levels after oophorectomy or menopause lead to increases in bone resorption andaccelerated bone loss. Bone is initially lost rapidly because the compensatory increase in bone formation isinadequate to offset resorptive losses. In addition to loss of estrogen, this imbalance between resorption andformation may be due to age-related impairment of osteoblasts or their precursors. In some women, these changeswill eventually lead to decreased bone mass, osteoporosis, and increased risk for fractures, particularly of the spine,hip, and wrist. Vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women.The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This bindingresults in activation of certain estrogenic pathways and blockade of others. Thus, raloxifene is an estrogenagonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM).Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to thepremenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of boneturnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in bone mineraldensity (BMD), and decreases in incidence of fractures.
|
| 41 |
|
Farydak
18
49
|
PANOBINOSTAT LACTATE |
Novartis |
February 2015 |
Disease/s that Drug Treats:Multiple myeloma
Indications and Usage:
18
FARYDAK, a histone deacetylase inhibitor, in combination with bortezomiband dexamethasone, is indicated for the treatment of patients with multiplemyeloma who have received at least 2 prior regimens, including bortezomiband an immunomodulatory agent. This indication is approved underaccelerated approval based on progression free survival. Continued approvalfor this indication may be contingent upon verification and description ofclinical benefit in confirmatory trials. (1)
DrugBank Targets:
-
Mechanism of Action:
18
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: FARYDAK is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs atnanomolar concentrations. HDACs catalyze the removal of acetyl groups from the lysine residues of histonesand some non-histone proteins. Inhibition of HDAC activity results in increased acetylation of histone proteins,an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation. In vitro,Reference ID: 3699607 panobinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/orapoptosis of some transformed cells. Increased levels of acetylated histones were observed in xenografts frommice that were treated with panobinostat. Panobinostat shows more cytotoxicity towards tumor cells comparedto normal cells.
|
| 42 |
|
Faslodex
18
49
|
FULVESTRANT |
AstraZeneca |
April 2002 |
Disease/s that Drug Treats:Hormone receptor positive metastatic breast cancer
Indications and Usage:
18
FASLODEX is an estrogen receptor antagonist indicated for the: Treatment of hormone receptor positive metastatic breast cancer inpostmenopausal women with disease progression followingantiestrogen therapy.
DrugBank Targets:
16
1. Estrogen receptor
Mechanism of Action:
18
Target: estrogen receptors on tumor cells
Action: antagonist
FDA: Many breast cancers have estrogen receptors (ER) and thegrowth of these tumors can be stimulated by estrogen.Fulvestrant is an estrogen receptor antagonist that binds to theestrogen receptor in a competitive manner with affinitycomparable to that of estradiol and downregulates the ERprotein in human breast cancer cells.In vitro studies demonstrated that fulvestrant is a reversibleinhibitor of the growth of tamoxifen-resistant, as well asestrogen-sensitive human breast cancer (MCF-7) cell lines. Inin vivo tumor studies, fulvestrant delayed the establishment oftumors from xenografts of human breast cancer MCF-7 cellsin nude mice. Fulvestrant inhibited the growth of establishedMCF-7 xenografts and of tamoxifen-resistant breast tumorxenografts.Fulvestrant showed no agonist-type effects in in vivouterotropic assays in immature or ovariectomized mice andrats. In in vivo studies in immature rats and ovariectomizedmonkeys, fulvestrant blocked the uterotrophic action ofestradiol. In postmenopausal women, the absence of changesin plasma concentrations of FSH and LH in response tofulvestrant treatment (250 mg monthly) suggests no peripheralsteroidal effects.
|
| 43 |
|
Femara
18
49
|
LETROZOLE |
Novartis |
January 2001 |
Disease/s that Drug Treats:Hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer
Indications and Usage:
18
Femara is an aromatase inhibitor indicated for: Adjuva nt treatment of postmenopausal women with hormone receptorpositive early brea st cancer (1.1) Extended adjuvant treatment of postmenopausal women with early brea stcancer who have received prior standard adju vant ta moxifen thera py (1.2) First a nd second-line treatment of postmenopausal women with hormonereceptor positive or unknown advanced breast cancer (1.3)
DrugBank Targets:
16
1. Cytochrome P450 19A1
Mechanism of Action:
18
Target: aromatase enzyme system
Action: inhibitor
FDA: The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breastcancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive orreceptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy,adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents).These interventions lead to decreased tumor mass or delayed progression of tumor growth in somewomen.In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, whichconverts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. Thesuppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore beachieved by specifically inhibiting the aromatase enzyme.Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits theconversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole isas effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression ofestrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to anincrease in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effecton adrenal mineralocorticoid or glucocorticoid synthesis.Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of womenwith letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown tosignificantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroidhormones.
|
| 44 |
|
Folotyn
18
49
|
PRALATREXATE |
Allos Therapeutics |
September 2009 |
Disease/s that Drug Treats:peripheral T-cell lymphoma
Indications and Usage:
18
FOLOTYN is a folate analog metabolic inhibitor indicated for the treatment ofpatients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Thisindication is based on overall response rate. Clinical benefit such asimprovement in progression-free survival or overall survival has not beendemonstrated. (1)
DrugBank Targets:
16
1. Dihydrofolate reductase;2. Thymidylate synthase
Mechanism of Action:
18
Target: dihydrofolate reductase
Action: inhibitor
FDA: Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also acompetitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition resultsin the depletion of thymidine and other biological molecules the synthesis of which depends on single carbontransfer.
|
| 45 |
|
Fusilev
18
|
LEVOLEUCOVORIN CALCIUM |
Spectrum Pharmaceuticals |
March of 2008 |
Disease/s that Drug Treats:rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate
Indications and Usage:
18
Fusilev is a folate analog indicated for: Rescue after high-dose methotrexate therapy in osteosarcoma. Diminishing the toxicity and counteracting the effects of impairedmethotrexate elimination and of inadvertent overdosage of folic acidantagonists. Use in combination chemotherapy with 5-fluorouracil in the palliativetreatment of patients with advanced metastatic colorectal cancer.(1)Limitations of UseFusilev is not approved for pernicious anemia and megaloblastic anemias.Improper use may cause a hematologic remission while neurologicmanifestations continue to progress. (1.1)
DrugBank Targets:
16
1. Thymidylate synthase
Mechanism of Action:
18
Target: therapeutic and toxic effects of folic acidantagonists / therapeutic and toxic effects of fluoropyrimidines used in cancer therapy
Action: counteract/enhance
FDA: 12.1.1 Levoleucovorin effects during high-dose methotrexate therapyLevoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not requirereduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of âonecarbonâmoieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acidantagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.12.1.2 Levoleucovorin effects in combination with 5-fluorouracilLevoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to andinhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily convertedto another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylatesynthase and thereby enhances the inhibition of this enzyme.
|
| 46 |
|
Gardasil
18
49
|
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine |
Merck |
June 2006 |
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:
18
GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets:
-
Mechanism of Action:
18
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.
|
| 47 |
|
Gazyva
18
49
|
OBINUTUZUMAB |
Genentech |
October of 2013 |
Disease/s that Drug Treats:previously untreated chronic lymphocytic leukemia
Indications and Usage:
18
GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and isindicated, in combination with chlorambucil, for the treatment of patients withpreviously untreated chronic lymphocytic leukemia. (1, 14)
DrugBank Targets:
16
1. B-lymphocyte antigen CD20
Mechanism of Action:
18
Target: CD20 antigen expressed on the surface of pre B- and mature B-lymphocytes
Action: engager of immune cells and/or activator of intracellular death signaling pathways and/or activator of the complement cascade
FDA: Obinutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surfaceof pre B- and mature B-lymphocytes. Upon binding to CD20, obinutuzumab mediates B-celllysis through (1) engagement of immune effector cells, (2) by directly activating intracellulardeath signaling pathways and/or (3) activation of the complement cascade. The immune effectorcell mechanisms include antibody-dependent cellular cytotoxicity and antibody-dependentcellular phagocytosis.
|
| 48 |
|
Gemzar
18
49
|
GEMCITABINE HYDROCHLORIDE |
Eli Lilly |
May 1996 |
Disease/s that Drug Treats:pancreatic cancer/Lung cancer
Indications and Usage:
18
Gemzar® is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovariancancer that has relapsed at least 6 months after completion of platinumbasedtherapy (1.1) in combination with paclitaxel, for first-line treatment of metastaticbreast cancer after failure of prior anthracycline-containing adjuvantchemotherapy, unless anthracyclines were clinically contraindicated(1.2) in combination with cisplatin for the treatment of non-small cell lungcancer (1.3) as a single agent for the treatment of pancreatic cancer (1.4)
DrugBank Targets:
16
1. DNA;2. Ribonucleoside-diphosphate reductase large subunit;3. Thymidylate synthase;4. UMP-CMP kinase
Mechanism of Action:
18
Target: ribonucleotide reductase
Action: inhibitor
FDA: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary.Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabinediphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleosidetriphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabinetriphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the actionof the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabinenucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results inthe initiation of apoptotic cell death.
|
| 49 |
|
Gilotrif
18
49
|
AFATINIB DIMALEATE |
Boehringer Ingelheim |
July 2013 |
Disease/s that Drug Treats:metastatic non-small cell lung cancer with EGFR mutations
Indications and Usage:
18
GILOTRIF is a kinase inhibitor indicated for the first-line treatment ofpatients with metastatic non-small cell lung cancer (NSCLC) whose tumorshave epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21(L858R) substitution mutations as detected by an FDA-approved test (1)Limitation of Use: Safety and efficacy of GILOTRIF have not beenestablished in patients whose tumors have other EGFR mutations (1)
DrugBank Targets:
16
1. Epidermal growth factor receptor;2. Receptor tyrosine-protein kinase erbB-2;3. Receptor tyrosine-protein kinase erbB-4
Mechanism of Action:
18
Target: tyrosine kinase autophosphorylation
Action: inhibitor
FDA: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) andirreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling.Afatinib demonstrated inhibition of autophosphorylation and in vitro proliferation of cell lines expressing wildtypeEGFR or those expressing selected EGFR exon 19 deletion mutations or exon 21 L858R mutations,including some with a secondary T790M mutation, at afatinib concentrations achieved, at least transiently, inpatients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors eitheroverexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.
|
| 50 |
|
Gleevec
18
49
|
IMATINIB MESYLATE |
Novartis |
May 2001 |
Disease/s that Drug Treats:chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:
18
Gleevec⢠(imatinib mesylate) is indicated for the treatment of newly diagnosed adultpatients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronicphase. Follow-up is limited. Page 10Gleevec is also indicated for the treatment of patients with Philadelphia chromosomepositive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronicphase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment ofpediatric patients with Ph+ chronic phase CML whose disease has recurred after stem celltransplant or who are resistant to interferon alpha therapy. There are no controlled trialsdemonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.Gleevec is also indicated for the treatment of patients with Kit (CD117) positiveunresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (SeeCLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec inGIST is based on objective response rate (see CLINICAL STUDIES). There are no controlledtrials demonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.
DrugBank Targets:
16
1. BCR/ABL fusion protein isoform X9;2. Mast/stem cell growth factor receptor Kit;3. RET proto-oncogene;4. High affinity nerve growth factor receptor;5. Macrophage colony-stimulating factor 1 receptor;6. Platelet-derived growth factor receptor alpha;7. Epithelial discoidin domain-containing receptor 1;8. Tyrosine-protein kinase ABL1;9. Platelet-derived growth factor receptor beta
Mechanism of Action:
18
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosinekinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosomeabnormality in chronic myeloid leukemia (CML). It inhibits proliferation and inducesapoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphiachromosome positive chronic myeloid leukemia. In colony formation assays using ex vivoperipheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positivecolonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as wellas Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derivedgrowth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- andSCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis ingastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
|
Drugs for Leiomyoma, Uterine (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 282)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Leuprolide |
Approved, Investigational |
Phase 4,Phase 3,Phase 1,Phase 2 |
|
53714-56-0 |
657181
3911
|
|
Synonyms:
(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone
5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate
5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
AC1L1GZK
AC1L9B44
AC1Q5OPO
Acetate, leuprolide
acetic acid
AR-1G9354
C07612
CID3911
CID441410
D00989
D08113
Enantone
Enantone (TN)
I04-0109
L001094
L002030
leuprolide
Leuprolide
Leuprolide acetate
Leuprolide monoacetate
|
Leuprolide, (DL-leu)-isomer
Leuprolide, (L-leu)-isomer
Leuprorelin
Leuprorelin (INN)
Leuprorelin acetate
Leuprorelin acetate (JAN)
Leuprorelina
Leuproreline
Leuprorelinum
L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
Lupron
Lupron (TN)
Monoacetate, leuprolide
N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
NSC377526
NSC746847
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5
PGlu-his-TRP-ser-tyr-D-leu-leu-arg-pro-NHC2H5
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet
PGlu-his-TRP-ser-tyr-D-leu-leu-arg-pro-nhet
TAP 144
TAP-144
|
|
| 2 |
|
Dienogest |
Approved |
Phase 4 |
|
65928-58-7 |
|
|
Synonyms:
17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile
17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one
dienogest
|
Dienogestril
Dienogestum
Endometrion
|
|
| 3 |
|
Goserelin |
Approved |
Phase 4,Phase 3,Phase 2 |
|
65807-02-5 |
47725
5311128
|
|
Synonyms:
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
AC1NSK1T
Acetate, goserelin
CID5311128
goserelin
Goserelin acetate
HMS2089D16
|
HS-2015
ICI 118
ICI-118630
ICI-118630Zoladex
MolPort-006-823-831
ZD-9393
Zoladex
|
|
| 4 |
|
Desogestrel |
Approved |
Phase 4 |
|
54024-22-5 |
40973
|
|
Synonyms:
(17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol
13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol
13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol
13-Ethyl-11-methylene-18,19-dinor-17a-pregn-4-en-20-yn-17-ol
13-Ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-ol
17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
54024-22-5
AC1L24T4
AC1Q282A
AC-308
alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17
alpha-Pregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-18,19-dinor-17
C07629
C22H30O
Cerazette
CHEBI:4453
CHEMBL1533
CID40973
D017135
D02367
|
DB00304
desogen
desogestrel
DESOGESTREL
Desogestrel (USAN/INN)
Desogestrel [USAN:BAN:INN]
Desogestrelum
Desogestrelum [INN-Latin]
EINECS 258-929-4
HSDB 3593
LMST02030104
LS-62079
Marvelon
MolPort-003-846-424
NCGC00167449-01
ORG 2969
Org2969
Org-2969
Organon brand OF desogestrel
Organon Brand of Desogestrel
UNII-81K9V7M3A3
ZINC04097416
|
|
| 5 |
|
Nandrolone decanoate |
Approved, Illicit |
Phase 4 |
|
360-70-3 |
9677
|
|
Synonyms:
17 beta-Hydroxyestr-4-en-3-one 17-decanoate
19-Nor-4-androstene-17 beta-ol-3-one 17-decanoate
19-nortestosterone decanoate
19-Nortestosterone decanoate
Decadurabolin
Deca-durabolin
Decadurobolin
|
Nandrolone 17β-decanoate
Nandrolone decanoic acid
Norandrostenolone decanoate
Nortestosterone decanoate
Retabolil
Retabolyl
|
|
| 6 |
|
Nandrolone phenpropionate |
Approved, Illicit, Investigational |
Phase 4 |
|
62-90-8 |
229455
|
|
Synonyms:
17 beta-Hydroxyestr-4-en-3-one hydrocinnamate
19NTPP
Durabolin
Fenobolin
Nadrolone phenylpropionate
Nadrolone phenylpropionic acid
Nandrolin
Nandrolon phenylpropionate
Nandrolon phenylpropionic acid
Nandrolone phenpropionate, (17alpha)-isomer
Nandrolone phenpropionic acid
Nandrolone phenylpionate
Nandrolone phenylpionic acid
Nandrolone phenylpropionate
|
Nandrolone phenylpropionic acid
Nerobolil
Nerobolyl
Norandrolone phenyl propionate
Norandrolone phenyl propionic acid
Norandrolone phenylpropionate
Norandrostenolone phenylpropionate
Norandrostenolone phenylpropionic acid
Nortestosterone phenylpropionate
Nortestosterone phenylpropionic acid
NPP
NTPP
Testosterone phenylpropionate
|
|
| 7 |
|
Hyaluronic acid |
Approved, Vet_approved |
Phase 4 |
|
9004-61-9 |
53477741
|
|
Synonyms:
|
| 8 |
|
Dimenhydrinate |
Approved |
Phase 4 |
|
523-87-5 |
441281
|
|
Synonyms:
(O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide
2-benzhydryloxyethyl(dimethyl)azanium
8-chloro-1,3-dimethyl-2-oxopurin-6-olate
8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
AC1L9AVV
Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline
CAS-523-87-5
CHEBI:4604
CID441281
D00520
DB00985
Dimenhidrinato
|
Dimenhydrinate (JP15/USP/INN)
Dimenhydrinatum
diphenhydramine 8-chlorotheophyllinate
diphenhydramine 8-chlorotheophylline
Diphenhydramine theoclate
Dramamine (TN)
HMS1568F12
N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
NCGC00017026-01
O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate
Prestwick_892
β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
|
|
| 9 |
|
Misoprostol |
Approved |
Phase 4,Phase 2,Phase 3 |
|
59122-46-2 |
5282381
|
|
Synonyms:
(+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester
(11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester
59122-46-2
62015-39-8
AC1NQZZA
Ambap103601-27-0
apo Misoprostol
apo-Misoprostol
Apotex brand OF misoprostol
BRN 4155643
CCRIS 6859
CHEMBL606
CID5282381
Cytotec
Cytotec (TN)
D00419
DB00929
Glefos
Grunenthal brand OF misoprostol
GyMiso
HMS2090L10
HSDB 3573
I14-11712
Isprelor
M6807_SIGMA
Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate
methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate
methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
Misopess
misoprostol
|
Misoprostol (JAN/USAN/INN)
Misoprostol apotex brand
Misoprostol grunenthal brand
Misoprostol novopharm brand
Misoprostol pfizer brand
Misoprostol, (11alpha,13E)-isomer
Misoprostol, (11alpha,13E,16R)-isomer
Misoprostol, (11alpha,13Z)-(+-)-isomer
Misoprostol, (11alpha.13E,16S)-isomer
Misoprostol, (11beta,13E)-(+-)-isomer
Misoprostol, (11beta,13E,16R)-isomer
Misoprostol, (11beta,13E,16S)-isomer
Misoprostolum
Misoprostolum [INN-Latin]
Misotol
MLS000028863
MolPort-003-666-830
NCGC00162445-01
NCGC00162445-02
novo Misoprostol
novo-Misoprostol
Novopharm brand OF misoprostol
Pfizer brand OF misoprostol
SC 29333
SC-29333
SMP1_000193
SMR000058558
UNII-0E43V0BB57
XP-16J
|
|
| 10 |
|
Calcium Carbonate |
Approved, Investigational |
Phase 4,Phase 3 |
|
471-34-1 |
|
|
Synonyms:
Calcium carbonate (1:1)
Calciumcarbonat
Carbonate de calcium
Carbonato de calcio
Carbonic acid calcium salt (1:1)
|
Chalk
Kalziumkarbonat
Kohlensaurer kalk
Precipitated calcium carbonate
|
|
| 11 |
|
Tranexamic Acid |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
1197-18-8 |
5526
|
|
Synonyms:
08455_FLUKA
1197-17-7
1197-18-8
1ceb
3-14-00-00868 (Beilstein Handbook Reference)
4-(aminomethyl)cyclohexane-1-carboxylic acid
4-(Aminomethyl)cyclohexanecarboxylic acid
4-(Aminomethyl)-Cyclohexanecarboxylic Acid
857653_ALDRICH
A0236
AB00052260
AB1003647
AC1L1KJH
AC1Q50F3
AC1Q546D
AC1Q5U04
AC-4687
Acide tranexamique
Acide tranexamique [INN-French]
acido Tranexamico
Acido tranexamico
Acido tranexamico [INN-Spanish]
Acidum tranexamicum
Acidum tranexamicum [INN-Latin]
ALBB-006013
AMCA
AMCHA
AMH
Amikapron
Amstat
Anvitoff
AR-1F6595
BAY 3517
BPBio1_000069
BRN 2207452
BSPBio_000061
BSPBio_002837
Carxamin
CAS-1197-18-8
CHEBI:48669
CHEMBL292500
CHEMBL877
CID5526
cis-4-(Aminomethyl)cyclohexanecarboxylic acid
cis-4-Aminomethylcyclohexane-1-carboxylic acid
cis-AMCHA
CL 65336
CL-65336
Cyclocapron
Cyklokapron
Cyklokapron (TN)
D01136
DB00302
DivK1c_000655
DV 79
DV79
DV-79
EINECS 214-818-2
Emorhalt
Exacyl
Frenolyse
Hexapromin
Hexatron
HMS1568D03
HMS1921F08
HMS2092P03
HMS502A17
I04-0993
IDI1_000655
KABI 2161
KBio1_000655
KBio2_001871
KBio2_004439
KBio2_007007
KBio3_002337
KBioGR_000511
KBioSS_001871
|
LS-56611
LS-56612
LT00159441
Mastop
MolPort-001-792-390
MolPort-002-512-008
NCGC00016569-01
NCGC00016569-02
NCGC00016569-03
NCGC00094944-01
NCGC00094944-02
NINDS_000655
NSC 291305
NSC291305
Oprea1_786414
Prestwick_476
Prestwick0_000171
Prestwick1_000171
Prestwick2_000171
Prestwick3_000171
Rikavarin
Rikavarin (TN)
Rikavarin-S
RP 18,429
SPBio_000689
SPBio_001982
Spectrum_001391
SPECTRUM1502026
Spectrum2_000655
Spectrum3_001189
Spectrum4_000046
Spectrum5_001258
Spiramin
STK503668
STOCK1N-16183
t-AMCHA
Tamcha
Tranex
Tranexamate
tranexamic acid
Tranexamic acid (JP15/USAN/INN)
Tranexamic acid [USAN:INN:BAN:JAN]
Tranexamic acid cis-form
Tranexamsaeure
Tranexan
Tranexmate
tranexmic acid
Tranexmic acid
Tranhexamate
Tranhexamic acid
trans AMCHA
Trans AMCHA
Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid
trans-1-Aminomethylcyclohexane-4-carboxylic acid
Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylate
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylate
trans-4-aminomethylcyclohexane-1-carboxylic acid
trans-4-Aminomethylcyclohexane-1-carboxylic acid
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylIC ACID
trans-Amcha
Transamin
Transamin (TN)
Transamlon
Trans-p-(Aminomethyl)cyclohexanecarboxylic
trans-p-(Aminomethyl)cyclohexanecarboxylic acid
trans-Tranexamate
trans-Tranexamic acid
Trasamlon
Ugurol
UNII-6T84R30KC1
WLN: L6TJ AVQ D1Z -T
|
|
| 12 |
|
Anastrozole |
Approved, Investigational |
Phase 4,Phase 3 |
|
120511-73-1 |
2187
|
|
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
AC1L1D49
AC-4234
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
Anastrazole
Anastrole
Anastrozol
anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
Astra brand OF anastrozole
AstraZeneca brand of anastrozole
AstraZeneca brand OF anastrozole
C08159
C090450
C17H19N5
|
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD1033
ZD-1033
Zeneca brand of anastrozole
Zeneca brand OF anastrozole
Zeneca ZD 1033
ZINC00000941
α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
| 13 |
|
Tocopherol |
Approved, Investigational |
Phase 4 |
|
1406-66-2 |
14986
|
|
Synonyms:
3,4-dihydro-2,7,8-Trimethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol
7,8-Dimethyltocol
7,8-dimethyltocolo-Xylotocopherol
Abortosan
adisseo Brand OF tocopherol
Alcala brand OF tocopherol acetate
Aliud brand OF tocopherol
Antioxidans e-hevert
Aquasol e
Arkopharma brand OF tocopherol acetate
AstraZeneca brand OF tocopherol acetate
Atarost brand OF tocopherol acetate
Ausrichter brand OF tocopherol
Auxina e
Balkanpharma brand OF tocopherol
Bayer brand OF tocopherol acetate
bio e
Biocur brand OF tocopherol acetate
biopto-e
Biosan
Bioweyxin
Blackmores brand OF tocopherol
Bottger brand OF tocopherol acetate
Cambridge laboratories brand OF tocopherol actetate
Dal e
Dal vita brand OF vitamin e succinate
Dal-e
Dal-vita brand OF vitamin e succinate
Davitamon
Dermorelle
Detulin
DL-alpha-Tocopherol
DL-a-Tocopherol
DL-α-tocopherol
Dragees, vitamin-e
e Ferol
e Mulsin
e Vicotrat
e Vitamin e
Ecoro
e-Ferol
Elex verla
Embial
e-Mulsin
Ephynal
Eplonat
Equivit e
Eu rho brand OF tocopherol
EUNOVA vitamin e
Eusovit
e-Vicotrat
EVI-mirale, vitamin-e
Evion
e-Vitamin-ratiopharm
GNR Pharma brand OF tocopherol actetate
GNR-Pharma brand OF tocopherol actetate
Grace brand OF tocopherol
Grunwalder brand OF tocopherol
g-Tocopherol
Hervert brand OF tocopherol acetate
Heyl brand OF tocopherol acetate
Hydrovit e
ICN brand OF tocopherol acetate
Infirmarius rovit brand OF tocopherol
Infirmarius-rovit brand OF tocopherol
Internation animal health brand OF tocopherol acetate
Jenapharm brand OF tocopherol
Kentucky brand OF tocopherol
Kohler brand OF tocopherol
Lasar
Malton e
medphano Brand OF tocopherol acetate
Merck brand OF tocopherol acetate
Methyltocols
Micorvit e
MIP brand OF tocopherol acetate
Mowivit vitamin e
Mucos brand OF tocopherol acetate
Organon brand OF tocopherol acetate
O-Xylotocopherol
puncto e
Ratiopharm brand OF tocopherol
Richelet brand OF tocopherol acetate
|
Richtavit e
Riemser brand OF tocopherol
Roche nicholas brand OF tocopherol acetate
Rodisma med brand OF tocopherol
Rodisma-med brand OF tocopherol
Sanavitan S
Sanum kehlbeck brand OF tocopherol actetate
Sanum-kehlbeck brand OF tocopherol actetate
Schwarzhaupt brand OF tocopherol acetate
Sciencex brand OF tocopherol acetate
Scot tussin brand OF tocopherol acetate
Scot-tussin brand OF tocopherol acetate
Snow-e muscle, energy and feritility
Spondyvit
Stadapharm brand OF tocopherol
Steigerwald brand OF tocopherol acetate
Strathmann brand OF tocopherol
tocoferol
tocoferoles
Tocolion
Tocopa
Tocopharm
Tocopherol
tocophérol
Tocopherol ausrichter brand
Tocopherol balkanpharma brand
Tocopherol bayer
Tocopherol grace brand
Tocopherol grunwalder brand
Tocopherol infirmarius-rovit brand
Tocopherol kentucky brand
Tocopherol ratiopharm brand
Tocopherol rodisma-med brand
Tocopherol stadapharm brand
Tocopherol togal brand
Tocopherol twardy brand
Tocopherol verla brand
Tocopherol wiedemann brand
Tocopherol worwag brand
Tocopherols
Tocovital
Togal brand OF tocopherol
Togasan vitamin e
Troyapharm brand OF tocopherol acetate
Twardy brand OF tocopherol
Unique e
uno Vit
uno-Vit
UnoVit
Verla brand OF tocopherol
Veyx brand OF tocopherol
Vibolex
Vit e hydrosol
Vit. e stada
Vita e
Vita plus e
Vita-e
VitaE
Vitagutt vitamin e
Vitamin e al
Vitamin e dragees
Vitamin e evi mirale
Vitamin e gamma
Vitamin e MP
Vitamin e natur
Vitamin e sanum
Vitamin e suspension
Vitamin e, mowivit
Vitamin e, togasan
Vitamin e, vitagutt
Vitamin emp
Vitamin e-MP
Vitamin-e dragees
Vitamine e GNR
Vitamin-e evi-mirale
Vita-plus e
VitaPlus e
Vitazell
Wiedemann brand OF tocopherol
Wiedemann brand OF vitamin e succinate
Woelm brand OF tocopherol acetate
Worwag brand OF tocopherol
γ-tocopherol
|
|
| 14 |
|
Nicotinamide |
Approved, Investigational |
Phase 4 |
|
98-92-0 |
936
|
|
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
37321-14-5
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC1L1ACZ
AC1Q4ZFV
AC-907/25014114
Acid amide
AI3-02906
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra brand OF niacinamide
Astra Brand of Niacinamide
Austrovit PP
b 3, Vitamin
B 3, Vitamin
b3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
beta-Pyridinecarboxamide
bmse000281
b-Pyridinecarboxamide
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
Factor PP
Hansamid
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm brand OF niacinamide
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
Jenapharm, nicotinsäureamid
LS-2051
m-(Aminocarbonyl)pyridine
Mediatric
Merck brand OF niacinamide
Merck Brand of Niacinamide
MLS000069714
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
Nandervit-N
NCGC00093354-03
NCGC00093354-04
nchembio.154-comp4
nchembio.73-comp6
Niacevit
Niacin
niacin - Vitamin B3
niacinamide
Niacinamide
Niacinamide (USP)
Niacinamide [USAN]
|
Niacinamide astra brand
Niacinamide Astra Brand
Niacinamide jenapharm brand
Niacinamide Jenapharm Brand
Niacinamide merck brand
Niacinamide Merck Brand
Niacinamide pharmagenix brand
Niacinamide Pharmagenix Brand
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
nicotinamide
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotinate amide
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid [German]
Nicotinsaureamid Jenapharm
Nicotinsäureamid jenapharm
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
niko-Tamin
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
NSC 13128
NSC13128
NSC27452
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix brand OF niacinamide
Pharmagenix Brand of Niacinamide
PP-Faktor
Propamine a
pyridine-3-carboxamide
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
Savacotyl
SGCUT00176
SMR000058212
to_000073
UNII-25X51I8RD4
Vi-nicotyl
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin b 3
Vitamin B 3
Vitamin b3
Vitamin H1
vitamin PP
Vitamin PP
Witamina PP
WLN: T6NJ CVZ
ZINC00005878
β-pyridinecarboxamide
|
|
| 15 |
|
Methylcobalamin |
Approved, Experimental, Investigational |
Phase 4 |
|
13422-55-4 |
|
|
Synonyms:
Co-methylcobalamin
CO-METHYLCOBALAMIN
MeCbl
mecobalamin
|
Mecobalamin
methyl(III)cobalamin
Methyl(III)cobalamin
Methylcobalamin
|
|
| 16 |
|
Hydroxocobalamin |
Approved |
Phase 4 |
|
13422-51-0 |
11953898
44475014
|
|
Synonyms:
13422-51-0
22465-48-1
78091-12-0
8017-22-9
a-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
Acti-B12
alpha Cobione
alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
AlphaRedisol
AlphaRedisol (TN)
Axion
Axlon
Benzimidazolyl ribofuranosyl phosphate deriv.
C08230
C62H85CoN13O15P
CHEBI:27786
CHEMBL1200742
CHEMBL235822
CID11622291
CID11953898
CID5460373
CID6433575
CID6474319
Ciplamin H
Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide
Cobalex
Cobalin H
Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-a-D-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-delta-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt
Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'- ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole
Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole
Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole
Codroxomin
Cyanokit
Cyanokit (TN)
D01027
DB00200
Depogamma
Docclan
Docelan
Docelvita
Docevita
Droxomin
Ducobee hy
Ducobee-Hy
Duradoce
Duralta-12
EINECS 236-533-2
Hidroxocobalamina
Hidroxocobalamina [INN-Spanish]
HSDB 3342
Hydro Cobex
|
Hydrobamine
Hydrocobalamin
Hydrogrisevit
Hydrovit
Hydroxocobalamin
Hydroxo-cobalamin
HYDROXOCOBALAMIN
Hydroxocobalamin (JAN/USP/INN)
Hydroxocobalamin [USAN:INN:BAN:JAN]
Hydroxocobalamin acetate
Hydroxocobalamin anhydrous
Hydroxocobalamin monohydrochloride
Hydroxocobalamin Vitamin B12
Hydroxocobalamin(alkaline soln.), OH- replaces CN- in Cyanocobalamin)
Hydroxocobalaminacetat
Hydroxocobalamine
Hydroxocobalamine [INN-French]
Hydroxocobalaminum
Hydroxocobalaminum [INN-Latin]
Hydroxocobalaminum anhydrous
Hydroxocobemine
Hydroxomin
Hydroxy Cobal
Hydroxy vitamin B12
Hydroxycob(lll)alamin
Hydroxycobalamin
Hydroxycobalamine
Hyxobamine
Idrogrisevit
Idrossocobalamina
Idrossocobalamina [DCIT]
LS-54607
Lyovit-H
Neo-Betalin 12
Neo-cytamen
Neo-macrabin
Neo-rojamin
Ohb12
OH-Cbl
OH-CBL
OH-Duphar
Oxobemin
Oxolamine (arcum)
Primabalt RP
Redisol-H
S1668_Selleck
Sytobex-H
UNII-Q40X8H422O
Vibeden
Vitadurin
Vitamin B(sub 12a)
Vitamin B12a
vitamin B-12b
Vitamin b-12b
Vitamin B12b
Vitamin B-12b
|
|
| 17 |
|
Ferrous fumarate |
Approved |
Phase 4 |
|
141-01-5 |
|
|
Synonyms:
|
| 18 |
|
Zinc oxide |
Approved |
Phase 4 |
|
1314-13-2 |
|
|
Synonyms:
óxido de cinc
oxyde de zinc
Zinc (as oxide)
Zinc (as zinc oxide)
|
Zinc white
Zinci oxydum
Zincum oxydatum
Zinkoxid
|
|
| 19 |
|
Zinc |
Approved, Investigational |
Phase 4 |
|
7440-66-6 |
|
|
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
| 20 |
|
leucovorin |
Approved |
Phase 4 |
|
58-05-9 |
6006
143
|
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
Acid, folinic
Acide folinique
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
folinate
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
| 21 |
|
Letrozole |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1 |
|
112809-51-5 |
3902
|
|
Synonyms:
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
Bio-0057
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
DB01006
|
FEM-345
Femara
Fémara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
Letoval
Letrozol
letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
LS-38788
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
Novartis brand OF letrozole
Novartis Brand of Letrozole
NSC719345
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
|
|
| 22 |
|
Cetrorelix |
Approved, Investigational |
Phase 4 |
|
120287-85-6 |
16129715
25074887
|
|
Synonyms:
120287-85-6
Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2
Cetrorelix
Cetrorelix (INN)
Cetrorelix acetate
Cetrorelix pamoate
Cetrorelixum
Cetrotide
Cetrotide (TN)
|
CHEBI:59224
CHEMBL1200490
D07665
HS-2008
N-Acetyl-1-(3-(2-naphthyl)alanine)-2-(4-chlorophenylalanine)-3-(3-(3-pyridyl)alanine)-6-citrulline-10-alanine-LHRH
N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide
N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide
SB 75
SB-75
|
|
| 23 |
|
Ethanol |
Approved |
Phase 4,Not Applicable |
|
64-17-5 |
702
|
|
Synonyms:
(C6-C9)Alkyl alcohol
[CH2Me(OH)]
[OEtH]
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
1-Hydroxyethane
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
absolute alcohol
Absolute alcohol
Absolute Alcohol
Absolute ethanol
Absolute Ethanol
Absolute ethyl alcohol
AC1L19TW
AC1Q31MM
Aethanol
Aethanol [German]
Aethylalkohol
AHD 2000
AI3-01706
Alcare hand degermer
Alcare Hand Degermer
alcohol
Alcohol
Alcohol (ethyl)
Alcohol (USP)
Alcohol [USP]
ALCOHOL 5% IN D5-W
Alcohol anhydrous
Alcohol Anhydrous
Alcohol dehydrated
Alcohol denatured
alcohol etilico
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Absolute
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, Dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, Diluted
Alcohol, ethyl
Alcohol, grain
Alcohol, Grain
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool ethylique
Alcool Ethylique
Alcool éthylique
Alcool etilico
Alcool Etilico
Algrain
Alkohol
Alkohol [German]
Alkoholu etylowego
Alkoholu Etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
bmse000297
C00469
C2H5OH
C2H6O
Caswell No. 426
Caswell No. 430
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
|
CHEMBL545
CID702
Colamine
Cologne spirit
Cologne Spirit
Cologne spirits
D000431
D00068
DB00898
Dehydrated alcohol
Dehydrated ethanol
Dehydrated Ethanol
Denatured alcohol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Denatured Ethanol
Desinfektol el
Desinfektol EL
Diluted alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
Envision Conditioner Pdd 9020
EOH
EOX
Esumiru WK 88
ETA
etanol
Etanol
Etanolo
Etanolo [Italian]
ethanol
éthanol
Ethanol (9CI)
Ethanol [JAN]
Ethanol 200 proof
Ethanol 200 Proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol Vapor
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl alc
ethyl alcohol
Ethyl alcohol
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl Alcohol Anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl Hydrate
Ethyl hydroxide
Ethyl Hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
EtOH
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
grain alcohol
Grain alcohol
Hinetoless
HSDB 531
HSDB 82
Hydroxyethane
HYDROXYETHYL GROUP
I14-12648
IMS 99
Infinity pure
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated spirit
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
MolPort-001-785-844
NCGC00091458-01
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
potato Alcohol
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spirits OF wine
spiritus vini
Spiritus vini
Spirt
SY Fresh M
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
UNII-3K9958V90M
USAF EK-1597
WLN: Q2
|
|
| 24 |
|
Mifepristone |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1 |
|
84371-65-3 |
55245
|
|
Synonyms:
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
(8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
11-(4-dimethylamino-PHENYL)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
11beta-(4-Dimethyl-?amino)-?phenyl-17beta-hydroxy-17-(1-propynyl)-?estra-4,9-dien-3-one
11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
122742-25-0
17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
404951-53-7
83203-42-3
84371-65-3
AC1L1IOO
AC1O62SB
Ambap84371-65-3
BIDD:PXR0123
BPBio1_000262
BRD-K37270826-001-04-5
BRN 5779404
BSPBio_000238
C07652
C-1073
C29H35NO2
CHEBI:50692
CHEMBL157
CHEMBL356066
CI-1073
CID55245
CID6445533
Contragest brand OF mifepristone
Contragest Brand of Mifepristone
Corlux
CPD000058481
D00585
D015735
Dacinostat
danco Brand OF mifepristone
Danco Brand of Mifepristone
DB00834
EC-000.2469
EU-0100801
Exelgyn brand OF mifepristone
Exelgyn Brand of Mifepristone
FT-0082666
HMS1568L20
HMS2052L05
HMS2090L22
HSCI1_000369
HSDB 6841
I14-11726
LAQ-824
Lopac0_000801
LS-192513
LS-64723
M 8046
M8046_SIGMA
|
Mifegyne
Mifégyne
Mifeprex
Mifeprex (TN)
Mifepriston
Mifepristona
Mifepristona [Spanish]
mifepristone
Mifépristone
Mifepristone (USAN/INN)
Mifepristone [USAN:INN:BAN]
Mifepristone contragest brand
Mifepristone Contragest Brand
Mifepristone danco brand
Mifepristone Danco Brand
Mifepristone exelgyn brand
Mifepristone Exelgyn Brand
Mifepristonum
Mifepristonum [Latin]
MLS000069785
MLS001074115
MolPort-003-849-222
NCGC00025179-05
NCGC00025179-08
NCGC00179632-01
nchembio.313-comp12
NVP-LAQ 824
NVP-LAQ824
NVP-LAQ824, Dacinostat, LAQ824
Pictovir
Pictovir (TM)
Prestwick_570
Prestwick0_000299
Prestwick1_000299
Prestwick2_000299
Prestwick3_000299
R 38486
R38486
R-38486
RU 38486
RU 486
RU 486-6
RU38486
RU-38486
RU486
RU-486
RU-486, MIFEPRISTONE
RU-486, RU-38486, Mifegyne, Mifeprex, Mifepristone
S1095_Selleck
S1611_Selleck
SAM001246881
SMR000058481
SPBio_002457
Spectrum5_002045
TL8005515
UNII-320T6RNW1F
UNII-V10P524501
VGX-410
VGX-410C
VX-410
ZINC03831128
ZK 98296
ZK98296
ZK-98296
|
|
| 25 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4,Phase 2,Not Applicable |
|
137-58-6 |
3676
|
|
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(diethylamino)-2',6'-Acetoxylidide
2-(Diethylamino)-2',6'-acetoxylidide
2-(diethylamino)-N-(2,6-Dimethylphenyl)acetamide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-diethylamino-2,6-Dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-Dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
|
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
| 26 |
|
Levonorgestrel |
Approved, Investigational |
Phase 4,Phase 2,Not Applicable |
|
17489-40-6, 797-63-7 |
13109
|
|
Synonyms:
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-20-yn-3-one
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one
(-)-Norgestrel
(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one
)-Norgestrel
121714-72-5
13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE
13-b-Ethyl-17a-ethynyl-17b-hydroxygon-4-en-3-one
13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one
13-Ethyl-17-a-ethynyl-17-b-hydroxy-4-gonen-3-one
13-Ethyl-17-a-ethynylgon-4-en-17-b-ol-3-one
13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one
13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one
13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one
13-Ethyl-17-α-ethynyl-17-β-hydroxy-4-gonen-3-one
13-Ethyl-17-α-ethynylgon-4-en-17-β-ol-3-one
13-β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one
17-a-Ethinyl-13-b-ethyl-17-b-hydroxy-4-estren-3-one
17a-Ethynyl-13b-ethyl-3-oxo-4-estren-17b-ol
17-a-Ethynyl-13-ethyl-19-nortestosterone
17a-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17a-Ethynyl-18-homo-19-nortestosterone
17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one
17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol
17alpha-Ethynyl-13-ethyl-19-nortestosterone
17-alpha-Ethynyl-13-ethyl-19-nortestosterone
17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one
17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17alpha-Ethynyl-18-homo-19-nortestosterone
17alpha-Ethynyl-18-homo-19-nor-testosterone
17-Ethynyl-18-methyl-19-nortestosterone
17-α-ethinyl-13-β-ethyl-17-β-hydroxy-4-estren-3-one
17-α-ethynyl-13-ethyl-19-nortestosterone
17α-ethynyl-13β-ethyl-3-oxo-4-estren-17β-ol
17α-ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17α-ethynyl-18-homo-19-nortestosterone
18,19-Dinor-4-pregnen-20-yn-3-one
18-Methyl-17-a-ethynyl-19-nortestosterone
18-Methyl-17-alpha-ethynyl-19-nortestosterone
18-Methyl-17-α-ethynyl-19-nortestosterone
18-Methylnorethisterone
4222-79-1
6533-00-2
72-HOURS
797-62-6
797-63-7
AC1L211U
AC1Q6OEV
Alcala brand OF levonorgestrel
alpha-Norgestrel
Aventis pharma brand OF levonorgestrel
BAY 86-5028
BAY86-5028
Berlex brand OF levonorgestrel
BIDD:PXR0194
Bio-0595
BPBio1_000932
BRD-K35189033-001-03-0
BRN 2391114
BSPBio_000846
C08149
C08153
Capronor
CCRIS 6525
CCRIS 9033
Cerazet
CHEBI:44593
CHEBI:6443
CHEMBL1389
CID13109
component of Lo/ovral
CPD000059117
D Norgestrel
D(−
d(-)-Norgestrel
D(-)-Norgestrel
D-(-)-Norgestrel
D00950
D00954
DB00367
DB00506
dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone
dl-Norgestrel
D-Norgestrel
Duofem
E-Gen-C
EINECS 212-349-8
EINECS 229-433-5
FH 122-A
Follistrel
Hexal brand OF levonorgestrel
HMS1570K08
HMS2051M08
HMS2090O06
HRA brand 1 OF levonorgestrel
HRA brand 2 OF levonorgestrel
HSDB 3595
HSDB 6483
Jadelle
L Norgestrel
Ld norgestrel
LD norgestrel [French]
Levlen
Levlen ED
Levonelle
Levonelle, D-Norgestrel, Levonova, Levonorgestrel
Levonorgestrel
Lévonorgestrel
Levonorgestrel (JAN/USP/INN)
Levonorgestrel [USAN:INN:BAN]
Levonorgestrel alcala brand
|
Levonorgestrel berlex brand
Levonorgestrel hexal brand
Levonorgestrel implants
Levonorgestrel paladin brand
Levonorgestrel wyeth brand
Levonorgestrelum
Levonorgestrelum [INN-Latin]
Levonova
Levora-21
Levora-28
LMST02030119
L-Norgestrel
LO/Ovral
Logynon ED
LS-62083
LS-62084
Methylnorethindrone
Microgest ED
Microgyn
Microgynon 21
Microgynon 28
Microgynon 30 ED
Microgynon CD
Microlut
Microlution
Microluton
Microval
Minivlar 30
Mirena
Mirena (TN)
MLS000069491
MLS000759484
MLS001074069
MolPort-002-510-453
Monofeme 28
Monovar
N2260_FLUKA
N2260_SIGMA
NCGC00159349-02
NCGC00159349-03
Neogest
Neogynon 21
Nordet
Nordette 21
Nordette 28
Norgeston
norgestrel
Norgestrel (JP15/USP/INN)
Norgestrel [Progestins]
Norgestrel [USAN:BAN:INN:JAN]
Norgestrel [USAN:INN:BAN:JAN]
Norgestrel-(-)-D
Norgestrelum
Norgestrelum [INN-Latin]
NorLevo
Norplant
NORPLANT
Norplant (TN)
Norplant 2
Norplant II
Norplant System in Plastic Container
Norplant2
Norplant-2
NSC744007
Ovoplex 30-150
Ovral-Lo
Ovranette
Ovrette
Ovrette (TN)
Paladin brand OF levonorgestrel
Plan b
Plan B
Postinor
Postinor-2
Prestwick_109
Prestwick0_000773
Prestwick1_000773
Prestwick2_000773
Prestwick3_000773
Preven
Rigevidon 21+7
S1727_Selleck
SAM001246694
Schering brand 1 OF levonorgestrel
Schering brand 2 OF levonorgestrel
Schering brand 3 OF levonorgestrel
SH 70850
SH 850
SMR000059117
SMR000653526
SOH-075
SPBio_002785
Stediril 30
Tetragynon
Triagynon
Triciclor
Trifeme 28
Trigoa
Tri-Levlen 21
Trinordiol 21
Trinordiol 28
Triphasil 21
Triphasil 28
Triquilar ED
Trivora
UNII-3J8Q1747Z2
UNII-5W7SIA7YZW
Vikela
Women's capital brand OF levonorgestrel
Wy 3707
Wy-3707
Wy-5104
Wyeth brand OF levonorgestrel
ZINC03814395
|
|
| 27 |
|
Everolimus |
Approved |
Phase 4 |
|
159351-69-6 |
6442177
|
|
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
|
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
| 28 |
|
Sirolimus |
Approved, Investigational |
Phase 4 |
|
53123-88-9 |
46835353
6436030
5284616
|
|
Synonyms:
(-)-rapamycin
(-)-Rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
| 29 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 4 |
|
22916-47-8 |
4189
|
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin iv
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (tn)
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
| 30 |
|
Progesterone |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
57-83-0 |
5994
|
|
Synonyms:
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
.beta.-Progesterone
.delta.(sup4)-Pregnene-3,20-dione
.delta.4-Pregnene-3,20-dione
17.alpha.-Progesterone
17alpha-progesterone
17alpha-Progesterone
17a-Progesterone
17α-progesterone
1dbb
1h60
257630-50-5
3,20-Pregnene-4
32104FB6-BF81-4F6E-83C2-024DEEAEB272
46665_FLUKA
46665_RIEDEL
4-Pregnen-3,20-dione
4-Pregnene-3,20-dione
57-83-0
753497-20-0
8012-32-6
8023-13-0
AC1L1LKF
AC-700
Agolutin
AI3-51682
Akrolutin
BB_NC-0185
beta-Progesterone
BHR-100
BIDD:ER0547
BIDD:PXR0094
bio-Luton
Bio-luton
bmse000482
BPBio1_000676
BRD-K64994968-001-03-6
BSPBio_000614
C00410
CCRIS 533
CHEBI:17026
CHEMBL103
CID5994
CIDR
CMC_13406
COL-1620
Colprosterone
component of Cyclogesterin
Corlutin
Corlutina
Corluvite
Corporin
corpus luteum hormone
Corpus luteum hormone
Corpus Luteum Hormone
CPD000058345
Crinone
Crinone (TN)
Crinone progesterone gel
Curretab
Cyclogest
Cyclogesterin
D00066
D4-Pregnene-3,20-dione
DB00396
Delalutin
delta(4)-Pregnene-3,20-dione
Delta(4)-pregnene-3,20-dione
Delta(4)-Pregnene-3,20-dione
delta(sup 4)-Pregnene-3,20-dione
delta(Sup4)-pregnene-3,20-dione
delta4-Pregnene-3,20-dione
DR-2011
Duraprogen
EINECS 200-350-6
Endometrin
Estima
ETI-411
EU-0100895
FE-999913
Flavolutan
Fologenon
Gelbkoerperhormon
Gelbkörperhormon
Gesterol
Gesterol 100
Gesterol 50
Gestiron
Gestone
Gestormone
Gestron
Glanducorpin
Gynlutin
Gynoluton
Gynolutone
HMS1569O16
HMS2051O05
HMS2090J07
Hormoflaveine
Hormoluton
HSDB 3389
Hydroxyprogesterone caproate
Hydroxyprogesterone caproic acid
Lingusorbs
lipo-Lutin
Lipolutin
Lipo-Lutin
LMST02030159
Lopac0_000895
LS-234
Lucorteum
Lucorteum sol
Lucorteum Sol
Lugesteron
Luteal hormone
Luteinique
Luteocrin normale
Luteodyn
Luteogan
luteohormone
Luteohormone
Luteol
Luteol (VAN)
Luteopur
Luteosan
Luteostab
Luteovis
Luteum
Lutex
|
Lutidon
Lutin
Lutinus
Lutociclina
Lutocuclin m
Lutocuclin M
Lutocyclin
Lutocyclin m
Lutocyclin M
Lutocylin
Lutocylol
Lutoform
Lutogyl
Lutogynon
Lutren
Lutromone
Membrettes
Methylpregnone
Micronized Progesterone
MLS000028517
MLS000758277
MLS001074187
MLS002222367
MolPort-001-794-643
MPA
Nalutron
Natural Progesterone
NCGC00022185-03
NCGC00022185-04
NCGC00022185-05
NCGC00022185-06
NCGC00022185-07
NCGC00022185-08
NCGC00022185-09
NCGC00090798-01
NCGC00090798-02
nchembio.2007.53-comp14
NCI60_042166
NSC 64377
NSC 9704
NSC64377
NSC9704
NSC-9704
P 0130
P0130_SIGMA
P0478
P3972_SIGMA
P6149_SIGMA
P7556_ALDRICH
P7556_SIGMA
P8783_SIGMA
P9776_SIGMA
Percutacrine
Percutacrine luteinique
Percutacrine Luteinique
Piaponon
Pranone
Pregn-4-en-3,20-dione
Pregn-4-ene-3,20-dione
Pregnene-3,20-dione
Pregnenedione
Prestwick_411
Prestwick0_000477
Prestwick1_000477
Prestwick2_000477
Prestwick3_000477
Primolut
Prochieve
Progeffik
Progekan
Progestan
Progestasert
Progesterol
Progesteron
Progesterona
Progesterona [INN-Spanish]
Progesterone
PROGESTERONE
Progestérone
Progesterone (JP15/USP/INN)
Progesterone [INN:BAN:JAN]
Progesterone [Progestins]
Progesterone, (13 alpha,17 alpha)-(+-)-isomer
Progesterone, (17 alpha)-isomer
Progesterone, (9 beta,10 alpha)-isomer
Progesterone, water-soluble
Progesterone: HBC complex
Progesterone-Water Soluble
Progesteronum
Progesteronum [INN-Latin]
Progestin
Progestogel
Progestol
Progeston
Progestone
Progestosol
Progestrel
Progestron
Progestronol
Projestaject
Prolets
Prolidon
Prolutin
Proluton
Prolutone
Prometrium
Prometrium (TN)
Prontogest
Protormone
S00293
S1705_Selleck
SAM001247039
SMR000058345
SMR000653542
SPBio_002553
Spectrum5_002053
SR-01000000088
SR-01000000088-5
Syngesterone
Syngestrets
Synovex S
Syntolutan
U 3672
UNII-4G7DS2Q64Y
Utrogest
Utrogestan
Vitarrine
WLN: L E5 B666 OV MUTJ A1 E1 FV1
ZINC04428529
δ(4)-pregnene-3,20-dione
|
|
| 31 |
|
Ketorolac |
Approved |
Phase 4 |
|
66635-83-4, 74103-06-3 |
3826
|
|
Synonyms:
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-isomer
(+-)-Ketorolac
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC1L1GSW
AC-545
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
I14-2832
Ketoralac
|
ketorolac
Ketorolac
Kétorolac
Ketorolac (INN)
Ketorolac [INN:BAN]
Ketorolac tromethamine
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
rac-Ketorolac
RS 37619
RS-37619
SBB067312
STL018674
Toradol
Toradol (TN)
UNII-YZI5105V0L
|
|
| 32 |
|
Ibuprofen |
Approved |
Phase 4,Not Applicable |
|
15687-27-1 |
3672
|
|
Synonyms:
(+-)-2-(P-Isobutylphenyl)propionate
(+-)-2-(P-Isobutylphenyl)propionic acid
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetate
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
(+-)-a-Methyl-4-(2-methylpropyl)benzeneacetate
(+-)-a-Methyl-4-(2-methylpropyl)benzeneacetic acid
(+-)-Ibuprofen
(+-)-P-Isobutylhydratropate
(+-)-P-Isobutylhydratropic acid
(+-)-α-methyl-4-(2-methylpropyl)benzeneacetate
(+-)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
(±)-2-(p-isobutylphenyl)propionic acid
(±)-ibuprofen
(±)-p-isobutylhydratropic acid
(±)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
(4-Isobutylphenyl)-alpha-methylacetate
(4-Isobutylphenyl)-alpha-methylacetic acid
(4-Isobutylphenyl)-a-methylacetate
(4-Isobutylphenyl)-a-methylacetic acid
(4-Isobutylphenyl)-α-methylacetate
(4-isobutylphenyl)-α-methylacetic acid
(4-Isobutylphenyl)-α-methylacetic acid
(RS)-ibuprofen
(RS)-Ibuprofen
139466-08-3
15687-27-1
2-(4-Isobutylphenyl)propanoate
2-(4-isobutylphenyl)propanoic acid
2-(4-Isobutylphenyl)propanoic acid
4-Isobutylhydratropate
4-isobutylhydratropic acid
4-Isobutylhydratropic acid
58560-75-1
a-(4-Isobutylphenyl)propionate
a-(4-Isobutylphenyl)propionic acid
a-(P-Isobutylphenyl)propionate
a-(P-Isobutylphenyl)propionic acid
AC-11312
AC1L1GGE
AC1Q1P84
AC1Q1P85
ACHES-N-PAIN
Act-3
Actiprofen
Adex 200
Adran
Advil
Advil (TN)
Advil Liqui-Gels
Ak+C2278tren
Alaxan
Algofen
alpha-(4-Isobutylphenyl)propionate
alpha-(4-Isobutylphenyl)propionic acid
alpha-(P-Isobutylphenyl)propionate
alpha-(P-Isobutylphenyl)propionic acid
alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
alpha-P-Isobutylphenylpropionate
alpha-P-Isobutylphenylpropionic acid
Aluminum salt ibuprofen
Amelior
Amersol
Am-Fam 400
Amibufen
Anafen
Anco
Andran
Anflagen
Antagil
Antalfene
Antarene
Antiflam
Apo-Ibuprofen
Apsifen
Apsifen-F
ARONIS23835
Artofen
Artril
Artril 300
Balkaprofen
BB_SC-1358
Betaprofen
BIDD:GT0050
Bloom
Bluton
BRN 2049713
Brofen
Brufanic
Brufen
Brufen 400
Bruflam
Brufort
Buburone
Bufeno
Bufigen
Bukrefen
Bupron
Buracaps
Burana
Butylenin
C01588
C13H18O2
Calcium salt ibuprofen
Cap-Profen
Carol
CCRIS 3223
Cesra
CHEBI:5855
CHEMBL521
Children's Advil
Children's Elixsure
Children's Ibuprofen
Children's Motrin
CID3672
Citalgan
Cobo
Codral
Combiflam
CPD000058184
Cunil
D00126
D007052
Daiprophen
Dalsy
Dansida
DB01050
Deep Relief
Dentigoa
Dibufen
Dignoflex
Dolgin
Dolgirid
Dolgit
Dolibu
Dolmaral
DOLO PUREN
Dolocyl
dolo-Dolgit
Dolo-Dolgit
Dolofen
Dolofen-F
Dolofin
Dolofort
Dologel
Dolomax
Doloren
Dolormin
Doltibil
Dolven
Donjust B
Dorival
Drin
Duafen
Duobrus
Dura-Ibu
Duralbuprofen
Dysdolen
Easifon
Ebufac
Emflam
Emflam-200
Emodin
Epobron
Eputex
Ergix
Esprenit
EU-0100691
Exneural
Faspic
Femadon
Femafen
Femapirin
Femidol
Fenbid
Fenbid Spansule
Fendol
Fenspan
Fibraflex
Gelufene
Gofen
Grefen
Gynofug
Haltran
HMS1920F15
HMS2089P05
HMS2091N03
HMS502M09
HSDB 3099
I 4883
I.V. solution, ibuprofen
I01-7039
I0415
I4883_SIGMA
I7905_SIAL
IB-100
Ibol
Ibren
Ibu
Ibu-attritin
Ibu-Attritin
Ibubest
Ibubeta
Ibucasen
Ibudol
Ibudolor
Ibufen
Ibuflamar
|
Ibufug
Ibugel
Ibugen
Ibugesic
Ibuhexal
Ibulagic
Ibular
Ibulav
Ibuleve
Ibulgan
Ibumed
Ibumerck
Ibumetin
Ibupirac
Ibuprin
Ibuprocin
ibuprofen
Ibuprofen i.v. solution
Ibuprofen zinc
Ibuprofen, (+-)-isomer
Ibuprofen, (R)-isomer
Ibuprofen, (S)-isomer
Ibuprofen, aluminum salt
Ibuprofen, calcium salt
Ibuprofen, copper (2+) salt
Ibuprofen, magnesium salt
Ibuprofen, potassium salt
Ibuprofen, sodium salt
Ibuprofen, zinc salt
Ibuprofene
Ibuprofeno
Ibuprofenum
Ibuprofen-zinc
Ibuprohm
Ibuprophen
Ibusal
Ibu-slo
Ibu-Slo
Ibu-slow
Ibu-Tab
Ibu-Tab 200
Ibutid
IDI1_000887
Ifen
Inabrin
Inflam
Inoven
IP 82
IP82
IP-82
Ipren
Irfen
Isodol
Jenaprofen
Junifen
Junior Strength Advil
Junior Strength Ibuprofen
Junior Strength Motrin
KBio1_000887
KBio2_001329
KBio2_003897
KBio2_006465
KBio3_001390
Kesan
Kratalgin
Lamidon
Lebrufen
Librofem
Lidifen
Liptan
Lopane
LS-7454
Magnesium salt ibuprofen
Malafene
Manypren
Medipren
Melfen
Mensoton
Midol
Midol 200
MLS000069733
MLS001146965
Moment
Motrin
Motrin (TN)
Motrin IB
Mynosedin
Nagifen-D
Napacetin
Narfen
NCI60_002065
Neobrufen
Neo-Helvagit
Neo-Mindol
NeoProfen
Nerofen
NINDS_000887
Noalgil
Nobafon
Nobfelon
Nobfen
Nobgen
Noritis
Norton
Novadol
Novogent
Novogent N
Novoprofen
Novo-Profen
NSC 256857
NSC256857
Nuprilan
Nuprin
Nurofen
Optifen
Opturem
Oralfene
Ostarin
Ostofen
Ozonol
Paduden
Panafen
Pantrop
Para-Isobutylhydratropic Acid
Paxofen
Pediaprofen
PediaProfen
Pedia-Profen
Pediatric Advil
Perofen
P-Isobutyl-2-phenylpropionate
P-Isobutyl-2-phenylpropionic acid
P-Isobutylhydratropate
P-Isobutylhydratropic acid
P-Isobutylhydratropic Acid
Potassium salt ibuprofen
Proartinal
Profen
Proflex
Provon
Quadrax
R.D. 13621
Rafen
Ranofen
RD 13621
Rebugen
Relcofen
Rhinadvil
Rofen
Roidenin
Rufen
Rufin
Rupan
Sadefen
Salivia
Salprofen
Salt ibuprofen, magnesium
Salt ibuprofen, sodium
Salt ibuprofen, zinc
SAM002264619
Seclodin
Sednafen
Seklodin
Seskafen
Siyafen
SMR000058184
Sodium salt ibuprofen
Solpaflex
Solufen
SPBio_000178
Stelar
STK177358
Sugafen
Suprafen
Suspren
Syntofene
Tabalon
Tabalon 400
Tab-Profen
Tatanal
Tempil
TL8001184
Tofen
Togal N
Tonal
Trauma dolgit gel
Trauma-dolgit gel
TraumaDolgit gel
Trendar
U 18573
U-18,573
U-18573
UCB 79171
Unipron
Upfen
Uprofen
Urem
VUFB 9649
Zafen
Zinc salt ibuprofen
Zofen
α-(4-isobutylphenyl)propionate
α-(4-isobutylphenyl)propionic acid
α-(P-isobutylphenyl)propionate
α-(p-isobutylphenyl)propionic acid
α-(P-isobutylphenyl)propionic acid
|
|
| 33 |
|
Acetaminophen |
Approved |
Phase 4 |
|
103-90-2 |
1983
|
|
Synonyms:
4-(acetylamino)Phenol
4-(Acetylamino)phenol
4-acetamidophenol
4-Acetamidophenol
4-Acetaminophenol
4'-hydroxyacetanilide
4'-Hydroxyacetanilide
4-Hydroxyacetanilide
4-Hydroxyanilid kyseliny octove
A.F. anacin
Abenol
Abensanil
Abrol
Abrolet
AC1Q1KYJ
AC1Q1KYK
Acamol
Accu-tap
Accu-Tap
Acenol
Acephen
Acertol
Aceta elixir
Aceta Elixir
Aceta tablets
Aceta Tablets
Acetaco
Acetagesic
Acetalgin
Acetaminofen
Acetaminofén
Acetaminophen uniserts
Acetaminophene
Acétaminophène
Acetamol
Acetavance
Acetofen
Actamin
Actamin extra
Actamin super
Actifed plus
Actifed Plus
Actimol
Actimol chewable tablets
Actimol children's suspension
Actimol infants' suspension
Actimol junior strength caplets
Actron
Afebrin
Afebryl
Aferadol
Algesidal
Algina
Algomol
Algotropyl
Allay
alpha-Per
Alpiny
Alpinyl
Alvedon
Amadil
Aminofen
Aminofen max
Anacin
Anacin 3
Anacin-3
Anacin-3 extra strength
Anadin dla dzieci
Anaflon
Analter
Anapap
Andox
Anelix
Anexsia
Anexsia 10/660
Anexsia 5/325
Anexsia 7.5/325
Anexsia 7.5/650
Anhiba
Anoquan
Anti-algos
Antidol
Anuphen
Apacet
Apacet capsules
Apacet elixir
Apacet extra strength caplets
Apacet extra strength tablets
Apacet regular strength tablets
Apadon
Apamid
Apamide
APAP
a-Per
A-Per
Apitrelal
apo-Acetaminophen
Arfen
Arthralgen
Asetam
Asomal
Aspac
Aspirin free anacin maximum strength caplets
Aspirin free anacin maximum strength gel caplets
Aspirin free anacin maximum strength tablets
Aspirin-free anacin
Aspirin-free excedrin caplets
Asplin
Atasol
Atasol caplets
Atasol drops
Atasol forte caplets
Atasol forte tablets
Atasol oral solution
Atasol tablets
Atralidon
Babikan
Bacetamol
Bancap
Bancap HC
Banesin
Bayer Select
Bayer select allergy-sinus
Bayer select head cold
Bayer select headache pain
Bayer select maximum strength headache pain relief formula
Bayer select menstrual multi-symptom
Bayer select sinus pain relief
Benmyo
Ben-u-ron
Bickie-mol
Biocetamol
Bucet
Butalbital
Butapap
Cadafen
Calapol
Calmanticold
Calonal
Calpol
Capital
Capital with codeine
Captin
Causalon
CCRIS 3
Cefalex
Cetadol
CHEBI:46195
Children'S acetaminophen elixir drops
Children'S acetaminophen oral solution
Children'S tylenol chewable
Claradol codeine
Clixodyne
Codabrol
COD-Acamol forte
Codalgin
Codapane
Codicet
Codisal
Codisal forte
Codoliprane
Codral pain relief
Cofamol
Co-Gesic
CO-Gesic
Conacetol
Contac cough & sore throat formula
Contra-schmerz P
Coricidin
Coricidin D
Coricidin sinus
Cosutone
Croix blanche
Cuponol
Curadon
Curpol
Custodial
D oliprane
Dafalgan
Dapa
Dapa X-S
Darocet
Darvocet
Darvocet-N 50
Datril
Datril extra-strength
Daygrip
Demilets
Deminofen
Democyl
Demogripal
Desfebre
Dhamol
DHC Plus
Dial-a-gesic
Dial-alpha-gesic
Dimindol
Dirox
Disprol
Dolcor
Dolefin
Dolegrippin
Dolene ap-65
Dolene AP-65
Dolgesic
Doliprane
Dolko
Dolofugin
Doloreduct
Dolorfug
Dolorol forte
Dolorstop
Dolotec
Dolprone
Dol-stop
Dorocoff
Dresan
Dristan cold no drowsiness
Dristancito
Drixoral Plus
Duaneo
Dularin
Duorol
Duracetamol
Duradyne DHC
Durapan
Dymadon
Dymadon co
Dymadon Co
Dymadon forte
Dypap
Ecosetol
Elixodyne
Empracet
Endecon
Enelfa
Eneril
Esgic
Esgic-plus
Eu-med
Eu-Med
Excedrin
Excedrin caplets
Excedrin extra strength caplets
Excipain
Exdol
Exdol strong
Fanalgic
Farmadol
Febranine
Febrectal
Febrectol
Febrex
Febricet
Febridol
Febrilix
Febrin
Febrinol
febro-Gesic
Febro-Gesic
Febrolin
Femcet
Fendon
Fensum
Fepanil
Fever All
Feverall
Feverall junior strength
Feverall sprinkle caps junior strength
Fevor
Finimal
Finiweh
Fioricet
Fluparmol
Fortalidon P
Freka-cetamol
Gattaphen T
Gelocatil
Geluprane
Genapap
Genapap children's elixir
Genapap children's tablets
Genapap extra strength caplets
Genapap extra strength tablets
Genapap regular strength tablets
Genebs
Genebs extra strength caplets
Genebs regular strength tablets
Genebs X-tra
Geralgine-P
Gripin bebe
Gripin Bebe
Grippostad
Gynospasmine
Hedex
Helon N
Homoolan
Hycomine compound
Hydrocet
Hy-phen
Hy-Phen
Ildamol
Inalgex
Infadrops
Infants' feverall
Influbene N
Injectapap
Intensin
Janupap
Jin Gang
Junior disprol
Kataprin
KBio1_000660
Kinder finimal
Korum
Kratofin simplex
L024125
Labamol
Lekadol
Lemgrip
Lemsip
Lestemp
Liqiprine
Liquagesic
Liquigesic co
Liquiprin
Liquiprin children's elixir
Liquiprin infants" drops
Lonarid
Lonarid mono
Lonarid Mono
Lorcet-HD
Lortab
Lupocet
Lyteca
Lyteca syrup
Lyteca Syrup
Magnidol
Malex N
Malgis
Malidens
Maxadol
Medigesic plus
Medinol paediatric
Medocodene
Melabon infantil
Mexalen
Midol maximum strength
Midol PM night time formula
Midol regular strength
Midol teen formula
Migraleve yellow
Minafen
Minoset
Miralgin
|
Momentum
mono Praecimed
Multin
N-(4-Hydroxyphenyl)acetamide
N-Acetyl-4-aminophenol
N-acetyl-p-aminophenol
N-Acetyl-P-aminophenol
Naldegesic
NAPA
Napafen
Napap
Naprinol
NCX 701
Nealgyl
Nebs
NEBS
NeoCitran
Neodol
Neodolito
neo-Fepramol
Neo-Fepramol
Neopap
Neotrend
Neuridon
New cortal for children
NilnOcen
Nina
Nobedon
Nodolex
NO-Febril
Noral
Norcet
Norco
NSC3991
O-Acetaminophenol
Ofirmev
Oltyl
Oralgan
Oraphen-PD
Ortensan
Oxycet
Oxycocet
Oxycodone 2.5/apap 500
Oxycodone 5/apap 500
P-(acetylamino)Phenol
Paceco
Pacemo
Pacemol
Pacet
p-acetamidophenol
P-Acetamidophenol
p-acetaminophenol
P-Acetaminophenol
p-Acetylaminophenol
P-Acetylaminophenol
Pacimol
Paedialgon
Paedol
Painex
Paldesic
Pamol
Panacete
Panadeine
Panadeine co
Panadeine Co
Panadiene
panado-Co
Panado-Co
panado-co Caplets
Panadol
Panadol extra strength
Panadol junior strength caplets
Panadol maximum strength caplets
Panadol maximum strength tablets
Panale ve
Panaleve
Panamax
Panasorb
Panasorbe
Panets
Panex
Panodil
Panofen
Pantalgin
Papa-Deine
Papa-deine #3
Papa-deine #4
Paracemol
Paracenol
Paracet
Paracetamol
Paracétamol
Paracetamol al
Paracetamol antipanin P
Paracetamol basics
Paracetamol BC
Paracetamol DC
Paracetamol dr. schmidgall
Paracetamol fecofar
Paracetamol genericon
Paracetamol hanseler
Paracetamol harkley
Paracetamol heumann
Paracetamol hexal
Paracetamol italfarmaco
Paracetamol nycomed
Paracetamol PB
Paracetamol raffo
Paracetamol ratiopharm
Paracetamol rosch
Paracetamol saar
Paracetamol smithkline beecham
Paracetamol stada
Paracetamol von CT
Paracetamol winthrop
Paracetamole
Paracetamolo
Paracetamolum
Paracetanol
Paracetol
Paracin
Paracod
Paracodol
Parador
Paradrops
Parakapton
Parake
Paralen
Paralief
Paralink
Paralyoc
Paramol
Paramolan
Paranox
Parapan
Parasedol
Parasin
Paraspen
Para-suppo
Para-Suppo
Para-tabs
Parcetol
Parelan
Parmol
Parogal
Paroma
Pasolind
Pasolind N
PCM Paracetamol lichtenstein
Pediapirin
Pediatrix
Pedric
Percocet
Percocet-5
Percocet-demi
Percogesic with codeine
Perdolan mono
Perfalgan
Pe-tam
Pe-Tam
Phenaphen
Phenaphen caplets
Phenaphen Caplets
Phenaphen w/codeine
Phendon
Phenipirin
Phogoglandin
Phrenilin
Phrenilin forte
Phrenilin Forte
p-hydroxy-acetanilid
p-hydroxyacetanilide
P-Hydroxyacetanilide
p-hydroxyphenolacetamide
P-Hydroxyphenolacetamide
Pinex
Piramin
Pirinasol
Plicet
Polmofen
Predimol
Predualito
Prestwick_13
Prodol
Prompt
Prontina
Propacet
Propacet 100
Proval #3
Puernol
Pulmofen
Pyregesic-C
Pyrigesic
Pyrinazine
Pyromed
Quiet world
Redutemp
Reliv
Remedol
Rhinex D-lay tablets
Rivalgyl
Robigesic
Robitussin night relief
Rockamol plus
Rounox
Roxicet
Roxicet 5/500
Roxilox
RubieMol
Rubophen
Rupemol
Salzone
Sanicet
Sanicopyrine
Scanol
Scentalgyl
Scherzatabletten rezeptur 534
Schmerzex
Sedalito
Sedapap
Semolacin
Servigesic
Seskamol
Setakop
Setamol
Setol
Sifenol
Sinaspril
Sinedol
Sine-OFF sinus medicine caplets
Sinmol
Sinubid
SK-Apap
Snaplets-FR
Spalt fur die nacht
Spalt N
SPBio_002836
ST Joseph aspirin-free
ST Joseph aspirin-free for children
St. joseph cold tablets for children
St. joseph fever reducer
St. Joseph Fever Reducer
Stanback
Stopain
Sudafed severe cold formula
Sudafed sinus
Sunetheton
Supac
Supadol mono
Supofen
Suppap
Suppap-120
Suppap-325
Suppap-650
Supramol-m
Supramol-M
Synalgos-Dc-A
Synalgos-DC-a
Tabalgin
Tachiprina
Talacen
Tapanol
Tapanol extra strength caplets
Tapanol extra strength tablets
Tapar
Tavist allergy/sinus/headache
Tavist Allergy/Sinus/Headache
Tazamol
Temlo
Tempanal
Tempra
Tempra caplets
Tempra chewable tablets
Tempra d.s
Tempra drops
Tempra syrup
Tencon
Termacet
Termalgin
Termalgine
Termofren
TheraFlu
Tibinide
Tibizide
Tiffy
Tisin
Tisiodrazida
Titralgan
Tizide
Tocris-1706
Toximer P
Tralgon
Treupel mon
Treupel N
Treuphadol
Triad
Triaminic sore throat formula
Triaprin
Tricoton
Tussapap
Ty lenol
Tycolet
TYL
Tylenol
Tylenol (TN)
Tylenol allergy sinus
Tylenol arthritis extended relief
Tylenol caplets
Tylenol children's chewable tablets
Tylenol children's elixir
Tylenol children's suspension liquid
Tylenol drops
Tylenol elixir
Tylenol extra strength adult liquid pain reliever
Tylenol extra strength caplets
Tylenol extra strength gelcaps
Tylenol extra strength tablets
Tylenol gelcaps
Tylenol infants drops
Tylenol infants" suspension drops
Tylenol junior strength caplets
Tylenol junior strength chewable tablets
Tylenol regular strength caplets
Tylenol regular strength tablets
Tylenol tablets
Tylex
Tylex CD
Tylol
Tylox
Tylox-325
Tymol
Ultracet
Upsanol
Utragin
Valadol
Valgesic
Valorin
Valorin extra
Valorin Extra
Vanquish
Veralgina
Vermidon
Verpol
Viclor richet
Vicodin
Vicodin es
Vicodin HP
Vips
Viruflu
Vivimed
Volpan
Wygesic
Zatinol
Zolben
|
|
| 34 |
|
Celecoxib |
Approved, Investigational |
Phase 4 |
|
169590-42-5 |
2662
|
|
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
| 35 |
|
Pregabalin |
Approved, Illicit, Investigational |
Phase 4 |
|
148553-50-8 |
5486971
|
|
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(R-)-3-Isobutyl gaba
(S)-3-(aminomethyl)-5-methylhexanoic acid
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3 Isobutyl gaba
3-(Aminomethyl)-5-methylhexanoic acid
3-isobutyl GABA
3-Isobutyl gaba
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
|
CID5486971
D02716
DB00230
FT-0080911
GABA, 3-isobutyl
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
|
|
| 36 |
|
Morphine |
Approved, Investigational |
Phase 4 |
|
57-27-2 |
5288826
|
|
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Anhydrous morphine
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
Chloride, morphine
CID5288826
Contin, MS
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
|
HSDB 2134
Infumorph
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
morfina
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine [BAN]
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine Sulfate
MORPHINE SULFATE
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
Sulfate, morphine
UNII-76I7G6D29C
Unkie
|
|
| 37 |
|
Prilocaine |
Approved |
Phase 4 |
|
721-50-6 |
4906
|
|
Synonyms:
2-(propylamino)-O-Propionotoluidide
2-(Propylamino)-o-propionotoluidide
2-(Propylamino)-O-propionotoluidide
2-Methyl-.alpha.-propylaminopropionanilide
2-Methyl-alpha-propylaminopropionanilide
2-Methyl-a-propylaminopropionanilide
2-Methyl-α-propylaminopropionanilide
721-50-6
AB00053665
AC1L1J7W
AC-2100
alpha-n-Propylamino-2-methylpropionanilide
alpha-N-propylamino-2-Methylpropionanilide
alpha-N-Propylamino-2-methylpropionanilide
Ambap1786-81-8
a-N-propylamino-2-Methylpropionanilide
Astra 1512
Astra 1515
Astra brand OF prilocaine hydrochloride
AstraZeneca brand OF prilocaine hydrochloride
BPBio1_000173
BRD-A53952395-003-05-3
BRN 2108498
BSPBio_000157
BSPBio_002604
C07531
C13H20N2O
CHEBI:8404
CHEMBL1194
CID4906
Citanest
Citanest octapressin
D00553
DB00750
Delvet brand OF prilocaine hydrochloride
DivK1c_000846
EINECS 211-957-0
HSDB 3386
I01-1860
IDI1_000846
Inibsa brand OF prilocaine hydrochloride
KBio1_000846
KBio2_002129
KBio2_004697
KBio2_007265
KBio3_001824
KBioGR_001883
KBioSS_002129
L 67
|
Lopac0_001005
LS-2304
MolPort-005-935-583
N-(2-Methylphenyl)-2-(propylamino)propanamide
N-(2-methylphenyl)-N(2)-propylalaninamide
N-(2-methylphenyl)-N2-propylalaninamide
N-[2-Methylphenyl]-2-[propylamino]propanamide
NCGC00015860-03
NCGC00162312-01
NINDS_000846
NSC 40027
NSC40027
o-Methyl-2-propylaminopropionanilide
O-Methyl-2-propylaminopropionanilide
o-Methyl-alpha-propylaminopropionanilide
O-Methyl-alpha-propylaminopropionanilide
O-Methyl-a-propylaminopropionanilide
O-Methyl-α-propylaminopropionanilide
Parnell brand OF prilocaine hydrochloride
Prestwick0_000199
Prestwick1_000199
Prestwick2_000199
Prestwick3_000199
Prilocain
Prilocaina
Prilocaina [INN-Spanish]
prilocaine
Prilocaïne
Prilocaine (USP/INN)
Prilocaine [USAN]
prilocaine base
Prilocaine base
Prilocaine hydrochloride
Prilocainum
Prilocainum [INN-Latin]
Propanamide, N-(2-methylphenyl)-2-(propylamino)- (9CI)
Propitocaine
Propitocaine (JAN)
S1619_Selleck
SPBio_001398
SPBio_002078
Spectrum_001649
Spectrum2_001549
Spectrum3_001052
Spectrum4_001192
Spectrum5_001175
UNII-046O35D44R
Xylonest
α-N-propylamino-2-methylpropionanilide
|
|
| 38 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4,Not Applicable |
|
2078-54-8 |
4943
|
|
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
| 39 |
|
Remifentanil |
Approved |
Phase 4,Not Applicable |
|
132875-61-7 |
60815
|
|
Synonyms:
132539-07-2 (mono-hydrochloride)
132875-61-7
1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester
3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
AC1L1TZ8
AC1Q5ZGR
BIDD:GT0029
C08021
CHEBI:8802
CHEMBL1005
CID60815
D08473
DB00899
DEA No. 9739
|
GI 87084B
GI 87084X
GI87084B
L001266
LS-115982
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
MolPort-004-286-006
REMIFENTANIL
Remifentanil (INN)
Remifentanil [INN:BAN]
Remifentanil hydrochloride
Remifentanil monohydrochloride
Remifentanyl
Ultiva
Ultiva (TN)
UNII-P10582JYYK
|
|
| 40 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 4,Not Applicable |
|
1177-87-3 |
|
|
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
9alpha-Fluoro-16alpha-methylprednisolone acetate
Dexamethasone 21-acetate
|
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasoni acetas
|
|
| 41 |
|
Nitrous oxide |
Approved, Vet_approved |
Phase 4 |
|
10024-97-2 |
948
|
|
Synonyms:
00583_FLUKA
10024-97-2
126386-65-0
129451-49-6
130835-71-1
147527-07-9
175876-44-5
295590_ALDRICH
794457-85-5
847968-13-2
850203-00-8
AC1L1ADZ
C00887
CCRIS 1225
CHEBI:17045
CHEMBL1234579
CID948
D00102
D009609
Diazyne 1-oxide
Dinitrogen monoxide
Dinitrogen oxide
Distickstoffmonoxid
e942
EINECS 233-032-0
Factitious air
FEMA 2779
FEMA No. 2779
Gas, laughing
Gas, Laughing
gaz hilarant
Gaz hilarant
HSDB 504
Hyponitrous acid anhydride
Lachgas
Laughing gas
LS-7622
N2O
Nitral
Nitrious oxide
|
Nitrogen hypoxide
Nitrogen monoxide
Nitrogen oxide (N2O)
Nitrogen protoxide
nitrogenium oxydulatum
Nitrogenium oxydulatum
nitrous oxide
Nitrous oxide (JP15/usp)
Nitrous oxide (JP15/USP)
Nitrous oxide (TN)
Nitrous oxide [Anaesthetics, volatile]
Nitrous oxide [JAN]
Nitrous oxide [UN1070] [Nonflammable gas]
Nitrous oxide [UN1070] [Nonflammable gas]
Nitrous oxide, compressed
Nitrous oxide, jan, usan
Nitrous oxide, refrigerated liquid
Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]
Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]
Nitrous-oxide
NITROUS-OXIDE
NNO
Oxide, nitrous
Oxide, Nitrous
oxido Nitroso
Oxido nitroso
Oxido nitroso [Spanish]
oxidodinitrogen(N--N)
Oxidodinitrogen(N--N)
oxyde nitreux
Oxyde nitreux
protoxyde d'azote
Protoxyde d'azote
Protoxyde d'azote [French]
R-744a
Stickdioxyd
Stickdioxyd [German]
Stickstoff(I)-oxid
UN1070
UN2201
|
|
| 42 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 4,Not Applicable |
|
50-02-2 |
5743
|
|
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
137098-19-2
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16α-methyl-9α-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-dehydro-16alpha -Methyl-9alpha -fluorohydrocortisone
1-dehydro-16alpha-Methyl-9alpha-fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-dehydro-16a-Methyl-9a-fluorohydrocortisone
1-dehydro-16α-methyl-9α-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9a-fluoro-16a-Methylprednisolone
9a-fluoro-16BETA-METHYLPREDNISOLONE
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -fluoro-16alpha -Methylprednisolone
9alpha-fluoro-16alpha-Methylprednisolone
9alpha-fluoro-16alpha-Methyl-prednisolone
9-alpha-fluoro-16-alpha-Methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-fluoro-11,17,21-Trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-fluoro-11alpha -Methylpregna-1,4-diene-3,20-dione
9-fluoro-16-Methylprednisolone
9α-fluoro-16α-methylprednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
Adexone
Aeroseb-D
Aeroseb-dex
Aeroseb-Dex
AI3-50934
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
Alcon Brand of Dexamethasone
alpha -fluoro-16-alpha -Methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
apo-Dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Azium (Veterinary)
BIDD:ER0494
BIDD:PXR0060
Bisu Ds
Bisu DS
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
C15643
C22H29FO5
Calonat
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
Corson
Corsone
Cortisumman
CPD001227192
CPD-10549
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-La
Decadron-LA
Decagel
Decaject
Decaject l.a.
Decaject L.A.
Decaject-l.a.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
Delta1-9alpha-fluoro-16alpha-Methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desametasone [DCIT]
Desamethasone
Desameton
Deseronil
DEX
Dexa
DEXA
Dexa mamallet
Dexa Mamallet
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexa-Cortidelt
Dexacortin
Dexa-cortisyl
Dexa-Cortisyl
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
dexamethasone
Dexamethasone
Dexamethasone (JP15/USP/INN)
|
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone Acetate
Dexamethasone alcohol
Dexamethasone Alcohol
Dexamethasone base
Dexamethasone Base
Dexamethasone intensol
Dexamethasone Intensol
Dexamethasone sodium phosphate
Dexamethasone Sodium Phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-Scheroson
Dexa-sine
Dexa-Sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dex-Ide
Dexinolon
Dexinoral
Dexone
Dexone 0.5
DEXONE 0.5
Dexone 0.75
DEXONE 0.75
Dexone 1.5
DEXONE 1.5
Dexone 4
DEXONE 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
DXM
Dxms
DXMS
ECR brand OF dexamethasone
ECR Brand of Dexamethasone
EINECS 200-003-9
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Foy Brand of Dexamethasone
FT-0080377
Gammacorten
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Elixir
Hexadrol Tablets
Hl-dex
Hl-Dex
HL-Dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
I06-1196
ICN brand OF dexamethasone
ICN Brand of Dexamethasone
IontoDex
isopto-Dex
Isopto-Dex
Lokalison F
Loverine
LS-7300
Luxazone
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merck Brand of Dexamethasone
Merz brand 1 OF dexamethasone
Merz Brand 1 of Dexamethasone
Merz brand 2 OF dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MK 125
MLS001055412
MLS001332507
MLS001332508
MolMap_000018
MolPort-003-846-433
Mymethasone
Naquasone (veterinary)
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
nchembio809-comp2
NCI60_003067
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC34521
Ocu-trol
Ocu-Trol
Oradexon
OTO-104
Pet derm III
Pet Derm Iii
Pet Derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
S1322_Selleck
SAM002548948
Sandoz dexamethasone
SGCUT00126
Sk-Dexamethasone
SK-Dexamethasone
SMP1_000092
SMR000857119
SMR001227192
Spectrum5_002019
Spoloven
ST50307091
Sunia sol D
Sunia Sol D
Superprednol
TL8003317
to_000038
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
|
|
| 43 |
|
Dinoprostone |
Approved |
Phase 4,Not Applicable |
|
363-24-6 |
5280360
|
|
Synonyms:
(-)-Prostaglandin e2
(15S)-Prostaglandin e2
(15S)-Prostaglandin E2
(5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11a,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-Oate
(5Z,11a,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-Oic acid
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-Oate
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic
(5Z,11alpha,13e,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-Oic acid
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid
(5Z,11α,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-Oate
(5Z,11α,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-Oic acid
(5Z,13E)-(15S)-11a,15-Dihydroxy-9-oxoprost-13-enoate
(5Z,13E)-(15S)-11a,15-Dihydroxy-9-oxoprost-13-enoic acid
(5Z,13E)-(15S)-11a,15-Dihydroxy-9-oxoprosta-5,13-dienoate
(5Z,13E)-(15S)-11a,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid
(5Z,13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoic acid
(5Z,13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid
(5Z,13E)-(15S)-11α,15-dihydroxy-9-oxoprost-13-enoate
(5Z,13E)-(15S)-11α,15-dihydroxy-9-oxoprost-13-enoic acid
(5Z,13E)-(15S)-11α,15-dihydroxy-9-oxoprosta-5,13-dienoate
(5Z,13E)-(15S)-11α,15-dihydroxy-9-oxoprosta-5,13-dienoic acid
(5Z,13E,15S)-11-alpha,15-Dihydroxy-9-oxoprost-5,13-dienoate
(5Z,13E,15S)-11-alpha,15-Dihydroxy-9-oxoprost-5,13-dienoic acid
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(e,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoate
(e,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid
(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid
(Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,e)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoate
(Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,e)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
(Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
[3H]PGE2
05D31BD5-818B-4A92-8CFC-BEC19926A5B3
363-24-6
5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)- (8CI)
5-trans-PGE2
7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
AC1NQWXW
AC-6098
alpha, PGE2
alpha, Prostaglandin e2
alpha, Prostaglandin E2
BML1-F07
BMS-279654 & PGE2
BRD-K26521938-001-04-9
BSPBio_001490
C00584
Cervidil
Cervidil (TN)
CHEBI:15551
CHEMBL548
CID5280360
D00079
D015232
DB00917
Dinoproston
Dinoprostona
Dinoprostona [INN-Spanish]
Dinoprostone
Dinoprostone (JAN/USP/INN)
Dinoprostone [USAN:INN:BAN:JAN]
Dinoprostone beta-Cyclodextrin Clathrate
|
Dinoprostone Prostaglandin E2
Dinoprostonum
Dinoprostonum [INN-Latin]
e2 alpha, Prostaglandin
E2 alpha, Prostaglandin
e2, Prostaglandin
E2, Prostaglandin
e2alpha, Prostaglandin
E2alpha, Prostaglandin
EINECS 206-656-6
Gel, prepidil
Gel, Prepidil
Glandin
HMS1361K12
HMS1791K12
HMS1989K12
HMS2089D17
IDI1_033960
l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
LMFA03010003
l-PGE2
l-Prostaglandin E2
L-Prostaglandin e2
LS-125823
Minprositin e2
Minprositin E2
Minprostin e2
Minprostin E2
MolPort-003-939-184
NCGC00092361-01
NCGC00092361-02
NCGC00092361-03
NCGC00092361-04
NCGC00092361-05
nchembio.106-comp6
nchembio.147-comp12
NSC 165560
NSC 196514
P0409_SIGMA
P5640_SIGMA
P6532_SIGMA
PGE2
PGE2 alpha
PGE2alpha
Prepidil
Prepidil (TN)
Prepidil gel
Prepidil Gel
Prestwick_793
Propess
Prostaglandin e
Prostaglandin E2
Prostaglandin e2 alpha
Prostaglandin E2 alpha
Prostaglandin e2alpha
Prostaglandin E2alpha
Prostarmon e
Prostarmon E
Prostarmon E2
Prostenon
Prostin
Prostin E
Prostin e2
Prostin E2
Prostin E2 (TN)
SMP2_000056
ST50826265
U 12062
U-12062
UNII-K7Q1JQR04M
|
|
| 44 |
|
Benzocaine |
Approved, Investigational |
Phase 4,Not Applicable |
|
94-09-7, 1994-09-7 |
2337
|
|
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl Aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
|
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-Aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-Aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
p-Ethoxycarboxylic Aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
| 45 |
|
Rocuronium |
Approved |
Phase 4 |
|
119302-91-9, 143558-00-3 |
441290
|
|
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
1-(17-(Acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
|
DB00728
Esmeron
Esmerone
HMS2090E03
NCGC00167433-01
Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, bromide
Rocuronium
Rocuronium bromide
Zemuron
|
|
| 46 |
|
tannic acid |
Approved |
Phase 4,Not Applicable |
|
|
|
| 47 |
|
Glycine |
Approved, Nutraceutical, Vet_approved |
Phase 4,Not Applicable |
|
56-40-6 |
750
|
|
Synonyms:
(1-13c)glycinato
(15N)Glycine
15527_RIEDEL
15527_SIAL
15743-44-9 (mono-potassium salt)
17829-66-2 (cobalt salt)
18875-39-3
2,2-dialkylglycines
2311-65-1
25718-94-9
29728-27-6 (monoammonium salt)
2-Aminoacetate
2-Aminoacetic acid
32817-15-5 (copper salt)
33226_RIEDEL
33226_SIAL
33242-26-1 (calcium salt)
35947-07-0 (calcium salt (2:1))
410225_SIAL
50046_FLUKA
50046_SIGMA
513-29-1 (sulfate (3:1))
52955-63-2
56-40-6
57678-19-0
6000-43-7 (hydrochloride)
6000-44-8 (mono-hydrochloride salt)
63183-41-5 (hydrochloride hydrogen carbonate)
71295-98-2 (phosphate (1:1))
7490-95-1 (hydrochloride (2:1)
7490-95-1 (hydrochloride (2:1))
7575-55-5
848646-45-7
87867-94-5
AB1002628
AB-131/40217813
AC1L19XW
AC1Q28JW
AC1Q53O0
Acid, aminoacetic
Acide aminoacetique
Acide aminoacetique [INN-French]
Acido aminoacetico
Acido aminoacetico [INN-Spanish]
Acidum aminoaceticum
Acidum aminoaceticum [INN-Latin]
Aciport
AI3-04085
AKOS000119626
amino-Acetate
Aminoacetate
aminoacetic acid
amino-Acetic acid
Aminoacetic acid
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER
Aminoazijnzuur
Aminoessigsaeure
Aminoessigsäure
Aminoethanoate
Aminoethanoic acid
Amitone
an alpha amino acid ester
AR-1A0345
AR-1A0532
B72BA06C-60E9-4A83-A24A-A2D7F465BB65
Biomol-NT_000195
bmse000089
BPBio1_001222
C00037
Calcium salt glycine
CCRIS 5915
CHEBI:15428
CHEBI:15705
CHEBI:16228
CHEMBL773
CID750
Cobalt salt glycine
Copper salt glycine
Corilin
CPD-8569
D00011
DB00145
EINECS 200-272-2
FEMA No. 3287
FT-0083159
G
G0099
G0317
G5417_SIGMA
|
G5523_SIGMA
G7126_SIGMA
G7403_SIGMA
G8790_SIGMA
G8898_SIGMA
Glicina
Glicina [INN-Spanish]
Glicoamin
gly
Gly
GLY (IUPAC abbrev)
Glycin
glycine
Glycine (JP15/USP)
Glycine [INN]
GLYCINE 1.5% IN PLASTIC CONTAINER
Glycine carbonate (1:1), monosodium salt
Glycine carbonate (2:1), monolithium salt
Glycine carbonate (2:1), monopotassium salt
Glycine carbonate (2:1), monosodium salt
Glycine hydrochloride
Glycine hydrochloride (2:1)
Glycine iron sulphate (1:1)
Glycine phosphate
Glycine phosphate (1:1)
Glycine sulfate (3:1)
GLYCINE, ACS
Glycine, calcium salt
Glycine, calcium salt (2:1)
Glycine, cobalt salt
Glycine, copper salt
Glycine, homopolymer (VAN)
Glycine, labeled with carbon-14
Glycine, monoammonium salt
Glycine, monopotasssium salt
Glycine, monosodium salt
Glycine, non-medical
Glycine, sodium hydrogen carbonate
Glycine-UL-14C hydrochloride
Glycinum
Glycinum [INN-Latin]
Glycocoll
Glycolixir
Glycosthene
Glykokoll
Glyzin
Gyn-hydralin
H2N-CH2-COOH
Hampshire glycine
Hgly
H-Gly-OH
HSDB 495
Hydrochloride, glycine
InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5
KST-1A2919
KST-1A8102
L001246
L-alpha-amino acids
Leimzucker
L-Glycine
LS-218
MolPort-000-871-607
Monoammonium salt glycine
Monopotasssium salt glycine
Monosodium salt glycine
NCGC00024503-01
NCGC00024503-02
nchem.554-comp2
nchembio.121-comp9
nchembio.145-comp33
nchembio.198-comp12
NChemBio.2007.13-comp1
nchembio.265-comp9
nchembio.266-comp30
NSC 25936
NSC25936
P8791_SIGMA
Padil
Phosphate, glycine
polyglycine
Polyglycine II
S04-0135
Salt glycine, monoammonium
Salt glycine, monosodium
Sucre de gelatine
Tocris-0219
UNII-TE7660XO1C
W328707_ALDRICH
WLN: Z1VQ
|
|
| 48 |
|
Vitamin E |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-02-9 |
14985
|
|
Synonyms:
(+)-alpha-Tocopherol
(+)-a-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-dihydro-2,5,7,8-Tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'r,8'r)-alpha-Tocopherol
(2R,4'r,8'r)-a-Tocopherol
(2R,4'r,8'r)-α-tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-trimethyltocol
5,7,8-Trimethyltocol
a-D-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
alpha-Tocopherol
Amino-Opti-E
Aquasol E
a-Tocopherol
D-alpha-Tocopherol
|
Daltose
D-a-Tocopherol
delta-alpha-Tocopherol
Denamone
d-α-tocopherol
D-α-tocopherol
E-200 I.U. Softgels
E-Complex-600
E-Ferol
Eprolin
E-Vitamin succinate
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-Tocopherol
RRR-alpha-Tocopheryl
Tocopherol
Vitamin e
Vitamin ea
Vitamin Plus E Softgells
Vitec
α-tocopherol
|
|
| 49 |
|
Pyridoxine |
Approved, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
65-23-6 |
1054
|
|
Synonyms:
(5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate
12001-78-4
2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0
2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine
2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]
2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine
2-methyl-4,5-dimethylol-pyridin-3-ol
3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride
3-Hydroxy-2-picoline-4,5-dimethanol
3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
3-Hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride
3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride
3-Hydroxy-4,5-dimethylol-alpha-picoline
3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride
3-Hydroxy-4,5-dimethylol-a-picoline
3-Hydroxy-4,5-dimethylol-α-picoline
4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol
4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride
4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol
47862_SUPELCO
4-Deoxypyridoxine 5'-phosphate
58-56-0
58-56-0 (HCL)
58-56-0 (hydrochloride)
5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol
5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
65-23-6
65-23-6 (Parent)
8059-24-3
85078-23-5
AC-12024
AC-14512
AC1L1AMH
AC1L1LMI
AC1L2XK2
AC1Q22HP
AC1Q2G66
AC1Q3F63
AC-907/25014218
Adermin hydrochloride
Adermine
Adermine hydrochloride
Aderomine hydrochloride
Aderoxin
Aderoxine
AI3-19016
AIDS006784
AIDS-006784
Alestrol
AR-1A6363
AR-1J1632
BB_NC-0050
Becilan
Beesix
Benadon
BIDD:PXR0180
bmse000288
Bonasanit
BPBio1_000646
BSPBio_000586
C00314
c1302
C8H11NO3
Campoviton 6
CAS-58-56-0
CBDivE_015627
CCRIS 1903
Cernevit-12
CHEBI:16709
CHEBI:30961
CHEMBL1200756
CHEMBL1364
CID104817
CID1054
CID6019
component of Alestrol
CPD0-1221
D02179
D025101
D08454
DB00165
EINECS 200-386-2
EINECS 200-603-0
EINECS 232-503-8
Godabion
Gravidox
Hexabetalin
Hexa-Betalin
Hexa-Betalin (R)
Hexa-betalin (TN)
Hexabione hydrochloride
Hexavibex
|
Hexermin
Hexermine
Hexobion
HMS1569N08
HMS2093L07
HSDB 1212
Hydoxin
I02-1897
I02-2297
KST-1A8556
LS-134393
LS-187072
LS-2332
MLS001074329
MLS002153915
MolPort-002-137-856
MolPort-002-319-991
MolPort-005-933-330
NCGC00016261-01
NCGC00164317-01
NCGC00180946-01
nchembio.93-comp1
Nestrex
NSC 36225
NSC36225
NSC36225 (HCL)
Oprea1_061614
P0561
P4722_SIAL
P5669_SIGMA
P6280_SIGMA
P8666_SIGMA
P9755_SIAL
Paxadon
Piridossina
Piridossina [DCIT]
Piridoxina
Piridoxina [INN-Spanish]
PN
PN HCl
Prestwick_925
Prestwick0_000623
Prestwick1_000623
Prestwick2_000623
Prestwick3_000623
Pydox
Pyridipca
Pyridox
Pyridoxin
Pyridoxin hydrochloride
pyridoxine
Pyridoxine
Pyridoxine (INN)
Pyridoxine [INN:BAN]
Pyridoxine chloride
Pyridoxine HCl
Pyridoxine hydrochloride
PYRIDOXINE HYDROCHLORIDE
Pyridoxine Hydrochloride (B6)
Pyridoxine hydrochloride (JP15/USP)
Pyridoxine hydrochloride [USAN:JAN]
PYRIDOXINE HYDROCHLORIDE, U.S.P.
Pyridoxine hydrogen chloride
Pyridoxine monohydrochloride
Pyridoxine, hydrochloride
Pyridoxine-HCl Microencapsulated
Pyridoxinium chloride
Pyridoxinum
Pyridoxinum [INN-Latin]
Pyridoxinum hydrochloricum
Pyridoxinum hydrochloricum (Hungarian)
Pyridoxol
Pyridoxol hydrochloride
Pyridoxol, hydrochloride
Pyridoxolum
Rodex
Rodex (R)
Rodex TD
SMP2_000230
SMR000674613
SPBio_002805
Spondylonal
STK177324
STOCK1N-08684
Tex Six T.R.
TimTec1_000657
UNII-68Y4CF58BV
UNII-KV2JZ1BI6Z
Vitamin B 6
vitamin B6
Vitamin b6
Vitamin B6
Vitamin B6-hydrochloride
Vitamin V6
Vitamin V6 (TN)
Vitamin-?B6
Vitamin-?B6 hydrochloride
Vitaped
WLN: T6NJ B1 CQ D1Q E1Q &GH
ZINC00049154
ZINC21983293
|
|
| 50 |
|
Niacin |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
59-67-6 |
938
|
|
Synonyms:
3 Pyridinecarboxylic acid
3-Carboxylpyridine
3-carboxypyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
Acide nicotinique
Acide Nicotinique
acido Nicotinico
Acido nicotinico
Acidum nicotinicum
Acidum Nicotinicum
Akotin
Aluminum salt, niacin
Anti-pellagra vitamin
Apelagrin
beta-Pyridinecarboxylate
beta-Pyridinecarboxylic acid
b-Pyridinecarboxylate
b-Pyridinecarboxylic acid
Daskil
Efacin
Enduracin
Hydrochloride, niacin
Induracin
Linic
Lithium nicotinate
m-Pyridinecarboxylate
m-Pyridinecarboxylic acid
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacin aluminum salt
Niacin ammonium salt
Niacin calcium salt
Niacin cobalt (2+) salt
Niacin copper (2+) salt
Niacin hydrochloride
Niacin iron (2+) salt
Niacin lithium salt
Niacin lithium salt, hemihydrate
Niacin magnesium salt
Niacin manganese (2+) salt
Niacin potassium salt
Niacin sodium salt
Niacin tartrate
|
Niacin tosylate
Niacin zinc salt
Niacina
Niacine
Niacor
Nicacid
Nicamin
Nicangin
nico 400
nico-400
Nico400
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
nico-Span
Nicotinate
Nicotinate, lithium
Nicotinic Acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
Pellagra preventive factor
Pellagrin
Pelonin
Potassium salt, niacin
PP Factor
Pyridine-b-carboxylate
Pyridine-b-carboxylic acid
Pyridine-beta-carboxylate
Pyridine-beta-carboxylic acid
Pyridine-β-carboxylate
pyridine-β-carboxylic acid
Pyridine-β-carboxylic acid
slo-Niacin
Sodium salt, niacin
Tartrate, niacin
Tosylate, niacin
Vitamin b3
Vitamin B3
Wampocap
β-pyridinecarboxylate
β-pyridinecarboxylic acid
|
|
Interventional clinical trials:
(show top 50)
(show all 366)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas |
Unknown status |
NCT02361905
|
Phase 4 |
ulipristal acetate;Leuprolide acetate |
| 2 |
Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin |
Unknown status |
NCT01738724
|
Phase 4 |
Dienogest;Goserelin;Desogestrel |
| 3 |
High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids |
Unknown status |
NCT01239641
|
Phase 4 |
|
| 4 |
Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma |
Unknown status |
NCT02361879
|
Phase 4 |
ulipristal acetate;Leuprolide acetate |
| 5 |
Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation |
Unknown status |
NCT02357563
|
Phase 4 |
ulipristal acetate;Leuprolide acetate |
| 6 |
IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure |
Unknown status |
NCT02601196
|
Phase 4 |
Ulipristal acetate |
| 7 |
Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy |
Unknown status |
NCT02288130
|
Phase 4 |
GnRHa;Ulipristal |
| 8 |
Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women |
Unknown status |
NCT02440750
|
Phase 4 |
Dienogest;Ulipristal acetate |
| 9 |
The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve |
Unknown status |
NCT02361892
|
Phase 4 |
ulipristal acetate |
| 10 |
Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy |
Unknown status |
NCT01632202
|
Phase 4 |
|
| 11 |
Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy |
Unknown status |
NCT02643186
|
Phase 4 |
preoperative vaginal misoprostol |
| 12 |
Fibroids in Women of Reproductive Age and Women Pregnancy |
Completed |
NCT02620345
|
Phase 4 |
Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 ) |
| 13 |
Pilot of Letrozole for Uterine Myomas |
Completed |
NCT02470741
|
Phase 4 |
Letrozole |
| 14 |
Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids |
Completed |
NCT00746031
|
Phase 4 |
GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix |
| 15 |
A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) |
Completed |
NCT00628901
|
Phase 4 |
|
| 16 |
The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. |
Completed |
NCT00995878
|
Phase 4 |
|
| 17 |
Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids |
Completed |
NCT00159328
|
Phase 4 |
|
| 18 |
A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy |
Recruiting |
NCT03210324
|
Phase 4 |
Mifepristone tablets |
| 19 |
Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization |
Completed |
NCT02293447
|
Phase 4 |
Lidocaine per-embolization;Lidocaine post-embolization |
| 20 |
Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids |
Recruiting |
NCT03317795
|
Phase 4 |
Levonorgestrel IUS;Tranexamic Acid |
| 21 |
Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis |
Recruiting |
NCT03500367
|
Phase 4 |
rapamycin |
| 22 |
Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future |
Completed |
NCT00180739
|
Phase 4 |
|
| 23 |
Ulipristal Use in Chinese Population |
Active, not recruiting |
NCT02825719
|
Phase 4 |
Ulipristal acetate;Ferrous sulphate;Tranexamic Acid |
| 24 |
Misoprostol for Reduction of Blood Loss During Fibroid Surgery |
Recruiting |
NCT02209545
|
Phase 4 |
Misoprostol;Placebo |
| 25 |
Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids |
Recruiting |
NCT03421639
|
Phase 4 |
Ulipristal acetate;Aromatase inhibitor plus GnRH analog |
| 26 |
Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure |
Completed |
NCT02227316
|
Phase 4 |
IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo |
| 27 |
Preemptive Analgesia Following Uterine Artery Embolization |
Terminated |
NCT01555073
|
Phase 4 |
pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group |
| 28 |
Combined Vaginal Misoprostol and Perivascular Vasopressin |
Recruiting |
NCT03815344
|
Phase 4 |
Standard;Standard-vaginal misoprostol |
| 29 |
Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators |
Completed |
NCT00743080
|
Phase 4 |
|
| 30 |
Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery |
Completed |
NCT01388907
|
Phase 4 |
|
| 31 |
Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial |
Completed |
NCT01393704
|
Phase 4 |
Vasopressin |
| 32 |
Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) |
Completed |
NCT02286063
|
Phase 4 |
Ambulatory Oxygen |
| 33 |
Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. |
Completed |
NCT01492179
|
Phase 4 |
Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine |
| 34 |
Comparing Two Types of Sedation to Gynaecological Patients |
Completed |
NCT01412632
|
Phase 4 |
Remifentanil, propofol and citanest |
| 35 |
Peritoneal Cavity Conditioning Decreases Pain, Inflammation and Adhesions |
Terminated |
NCT01344486
|
Phase 4 |
|
| 36 |
Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy |
Completed |
NCT02154932
|
Phase 4 |
2 doses 400 microgram misoprostol;single dose misoprostol |
| 37 |
Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis |
Withdrawn |
NCT03325868
|
Phase 4 |
Ulipristal Acetate |
| 38 |
Understanding Experimentally Induced Hot Flushes |
Completed |
NCT00455689
|
Phase 4 |
Leuprolide acetate |
| 39 |
Impact of Hot Flashes on Sleep and Mood Disturbance |
Completed |
NCT01116401
|
Phase 4 |
leuprolide |
| 40 |
Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery |
Enrolling by invitation |
NCT02812186
|
Phase 4 |
Rocuronium |
| 41 |
Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids |
Unknown status |
NCT02189083
|
Phase 3 |
TSD |
| 42 |
Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy |
Unknown status |
NCT01280045
|
Phase 3 |
|
| 43 |
Clinical Trial of Uterine Artery Embolization for Uterine Leiomyoma |
Unknown status |
NCT00821275
|
Phase 2, Phase 3 |
|
| 44 |
The Use of Doppler to Diagnose Myometrial Masses |
Unknown status |
NCT01833871
|
Phase 2, Phase 3 |
|
| 45 |
Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy |
Unknown status |
NCT01483417
|
Phase 3 |
|
| 46 |
Single-port Access Laparoscopic-assisted Vaginal Hysterectomy |
Unknown status |
NCT01048931
|
Phase 3 |
|
| 47 |
Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy |
Unknown status |
NCT02011659
|
Phase 3 |
Ramosetron |
| 48 |
3D Sonohysterography vs Hysteroscopy: Study for the Evaluation of Intrauterine Abnormalities |
Unknown status |
NCT02682433
|
Phase 3 |
|
| 49 |
Intravenous Tranexamic Acid Versus Pericervical Tourniquet To Decrease Blood Loss In Trans-Abdominal Myomectomy |
Unknown status |
NCT02733952
|
Phase 3 |
Tranexamic Acid |
| 50 |
Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound |
Withdrawn |
NCT02736435
|
Phase 3 |
leuprolide acetate for depot suspension |
|
